US20230295572A1 - Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells - Google Patents
Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells Download PDFInfo
- Publication number
- US20230295572A1 US20230295572A1 US18/187,554 US202318187554A US2023295572A1 US 20230295572 A1 US20230295572 A1 US 20230295572A1 US 202318187554 A US202318187554 A US 202318187554A US 2023295572 A1 US2023295572 A1 US 2023295572A1
- Authority
- US
- United States
- Prior art keywords
- mscs
- composition according
- cells
- induced
- trauma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 183
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 230000022159 cartilage development Effects 0.000 title claims description 13
- 230000001939 inductive effect Effects 0.000 title description 26
- 238000000034 method Methods 0.000 title description 26
- 230000002648 chondrogenic effect Effects 0.000 claims abstract description 49
- 210000002435 tendon Anatomy 0.000 claims abstract description 32
- 208000014674 injury Diseases 0.000 claims abstract description 29
- 230000008733 trauma Effects 0.000 claims abstract description 27
- 210000003041 ligament Anatomy 0.000 claims abstract description 22
- 210000000845 cartilage Anatomy 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 150
- 239000002609 medium Substances 0.000 claims description 76
- 241000283073 Equus caballus Species 0.000 claims description 65
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 64
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 230000003902 lesion Effects 0.000 claims description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 19
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 15
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- 208000030175 lameness Diseases 0.000 claims description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims description 13
- 239000011886 peripheral blood Substances 0.000 claims description 13
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 11
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 11
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 239000002577 cryoprotective agent Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 description 63
- 230000006698 induction Effects 0.000 description 43
- 241000283086 Equidae Species 0.000 description 42
- 230000006872 improvement Effects 0.000 description 36
- 239000003102 growth factor Substances 0.000 description 23
- 210000001074 muscle attachment cell Anatomy 0.000 description 21
- 238000010186 staining Methods 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 19
- 238000002604 ultrasonography Methods 0.000 description 18
- 239000012071 phase Substances 0.000 description 17
- 210000000130 stem cell Anatomy 0.000 description 16
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 13
- 108010009583 Transforming Growth Factors Proteins 0.000 description 12
- 102000009618 Transforming Growth Factors Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 102000012422 Collagen Type I Human genes 0.000 description 11
- 108010022452 Collagen Type I Proteins 0.000 description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 11
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 11
- 210000001612 chondrocyte Anatomy 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 239000000835 fiber Substances 0.000 description 11
- 238000002955 isolation Methods 0.000 description 11
- 229940096422 collagen type i Drugs 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 9
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 102000016284 Aggrecans Human genes 0.000 description 8
- 108010067219 Aggrecans Proteins 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 108010065472 Vimentin Proteins 0.000 description 8
- 102000013127 Vimentin Human genes 0.000 description 8
- 239000006481 glucose medium Substances 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 238000010257 thawing Methods 0.000 description 8
- 210000005048 vimentin Anatomy 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000001172 regenerating effect Effects 0.000 description 7
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004700 fetal blood Anatomy 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000003365 immunocytochemistry Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000002894 multi-fate stem cell Anatomy 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 102000001187 Collagen Type III Human genes 0.000 description 4
- 108010069502 Collagen Type III Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 4
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 4
- 241000710886 West Nile virus Species 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000009724 equine infectious anemia Diseases 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000003857 African horse sickness Diseases 0.000 description 3
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 3
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 3
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 3
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 3
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 3
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 3
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 3
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 3
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 3
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 3
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 3
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 3
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 3
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 3
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 3
- 201000003641 Glanders Diseases 0.000 description 3
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 3
- 102000018297 Immunoglobulin subtype Human genes 0.000 description 3
- 108050007411 Immunoglobulin subtype Proteins 0.000 description 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 3
- 206010023215 Joint effusion Diseases 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960004424 carbon dioxide Drugs 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 102000046949 human MSC Human genes 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 101710087047 Cytoskeleton-associated protein 4 Proteins 0.000 description 2
- 208000009514 Dourine Diseases 0.000 description 2
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 2
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241000878128 Malleus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 241000223104 Trypanosoma Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 101710140697 Tumor protein 63 Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 201000008680 babesiosis Diseases 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009816 chondrogenic differentiation Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000003235 crystal violet staining Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002331 malleus Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000010476 Respiratory Paralysis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100027881 Tumor protein 63 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940014381 adequan Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001433 inducive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/066—Tenocytes; Tendons, Ligaments
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/137—Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
Definitions
- the present invention relates to the field of methods and compositions for directing mesenchymal progenitor cells cultivated in vitro to differentiate into specific cell lineage pathways, and particularly to such directed lineage induction prior to, or at the time of, their implantation into a recipient or host for the therapeutic treatment of pathologic conditions in humans and other species.
- MSCs Mesenchymal stem cells
- the specific differentiation pathway which these cells enter depends upon various influences from mechanical influences and/or endogenous bioactive factors, such as growth factors, cytokines, and/or local micro-environmental conditions established by host tissues.
- Damage to the articular surfaces of synovial joints, or tendon and ligament lesions can arise from trauma, from diseases (e.g. osteoarthritis), and as a result of the aging process.
- most prescribed therapies include conservative treatments such as administration of NSAIDs, corticoid treatment, surgical treatments, bandaging, etc.
- the latter are often found to be ineffective and time-consuming.
- WO 1998 032 333 describes a process for producing chondrocytes from mesenchymal stem cells thereby using of a medium supplemented with growth factors from the transforming growth factor- ⁇ super-family.
- WO 2010 007 551 discloses a method for inducing tenogenesis whereby a cell medium comprising bon morphogenetic proteins.
- the present invention provides for a cell medium according to claim 1 and use of such cell medium for inducing chondrogenesis or tenogenesis according to claim 12 or 15 .
- the current invention furthermore relates to a method for inducing chondrogenesis or tenogenesis in isolated mesenchymal stem cells (MSCs) according to claim 18 and a composition according to claim 24 . Further embodiments of the invention are described in the dependent claims.
- the cell medium and methodology according to the current invention provides for an optimized manner of inducing tenogenesis or chondrogenesis in stem cells, obtaining a higher percentage of correctly induced cells. Furthermore, the cells according to the current invention are suitable for application in regenerative treatment.
- FIG. 1 A shows marker expression of chondrogenic specific markers in chondrogenic induced MSCs according to the current invention.
- FIG. 1 B shows induction of tenogenic specific markers in tenogenic induced MSCs.
- FIG. 2 A shows the tenogenic potential of human MSCs derived from adipose tissue (AT).
- FIG. 2 B shows the tenogenic potential of human MSCs derived from umbilical cord blood (UC).
- FIG. 2 C shows the tenogenic potential of human MSCs derived from bone-marrow derived MSCs (BM).
- FIG. 3 shows representative light microscopic images of peripheral blood (PB)-derived mesenchymal stem cells (MSCs) in their undifferentiated state and after tenogenic induction.
- PB peripheral blood
- MSCs mesenchymal stem cells
- FIG. 4 shows immunohistochemistry data which revealed that the tenogenic induced mesenchymal stem cells (MSCs) according to an embodiment of the current invention were all positive for smooth muscle actin (SMA).
- FIG. 5 shows immunohistochemistry data which revealed that some (arrows) of the tenogenic induced mesenchymal stem cells (MSCs) according to an embodiment of the current invention were positive for collagen type I. The typical tenogenic morphology and longitudinal orientation can be noticed on the images.
- FIG. 6 shows histograms representing the number of patients and the different scores they received from the veterinary practitioners (0-5) at approximately 6 weeks after treatment of their superficial digital flexor tendon (SDFT) or suspensory ligament (SL).
- SDFT superficial digital flexor tendon
- SL suspensory ligament
- FIG. 7 shows a longitudinal (left side) and transversal (right side) ultrasound image of a lesion (white circle) in the lateral edge of the superficial digital flexor tendon (SDFT) of a horse.
- SDFT superficial digital flexor tendon
- FIG. 8 shows an ultrasound image of a lesion (white circle) in the lateral branch of the suspensory ligament (SL) of a horse.
- SL suspensory ligament
- FIG. 9 shows representative light microscopic images at a 20 ⁇ magnification of equine peripheral blood (PB)-derived mesenchymal stem cells (MSCs) in their undifferentiated state and after tenogenic induction according to an embodiment of the current invention.
- PB peripheral blood
- MSCs mesenchymal stem cells
- FIG. 10 represents a timeline of a treatment and follow-up protocol used in the present study at different time points (T).
- FIG. 11 shows histograms which represent the number of patients and the different scores they received from the veterinary practitioners (0-5) at approximately 6 weeks and 4 months after treatment of their accessory ligament of the deep digital flexor tendon (ALDDFT).
- ADDFT deep digital flexor tendon
- FIG. 12 shows transversal (T) and longitudinal (L) ultrasound images of a lesion (white circle) in accessory ligament of the deep digital flexor tendon (ALDDFT) in 3 horses (H) before (left column) and 6 weeks after (right column) treatment with tenogenic induced allogenic mesenchymal stem cells (TC).
- T transversal
- L longitudinal
- H 3 horses
- TC tenogenic induced allogenic mesenchymal stem cells
- FIG. 13 shows representative images of peripheral blood (PB)-derived mesenchymal stem cells (MSCs) in their undifferentiated state (panels A & C) and chondrogenic induced according to an embodiment of the current invention (panels B & D) after Hematoxylin (panels A & B) and Crystal Violet (panels C & D) stainings.
- PB peripheral blood
- MSCs mesenchymal stem cells
- FIG. 14 shows the results of RT-PCR for the gene expression of collagen (Col) type II, aggrecan and cartilage oligomeric matrix protein (COMP) in the native MSCs (Control) and chondrogenic induced MSCs (Induced) according to the current invention. Values are given as the mean of three measurements ⁇ SEM.
- FIG. 15 shows representative images of peripheral blood (PB)-derived mesenchymal stem cells (MSCs) in their undifferentiated state (A & C) and chondrogenic induced (B & D) after Safranin O (A & B) and Alcian Blue (C & D) stainings. Glycosaminoglycan production (black arrows) can be noticed after induction. Scale bars represent 50 ⁇ m.
- PB peripheral blood
- MSCs mesenchymal stem cells
- FIG. 16 shows results of immunocytochemistry on cytospins using Ki67 (A), collagen (Col) type II (B), vimentin (C) and p63 (D).
- Ki67 A
- Col collagen
- B vimentin
- C vimentin
- D p63
- Native mesenchymal stem cells (MSCs) were negative for p63 and positive for Ki67, Col II and vimentin, whereas chondrogenic induced MSCs were positive for p63, Col II and vimentin and slightly positive for Ki67.
- Arrows indicate a decreased signal for Ki67 in some chondrogenic induced MSCs.
- the relevant isotype controls were negative.
- Scale bar represents 25 ⁇ m.
- FIG. 17 shows flow cytometic experiments which confirmed a very low expression of major histocompatibility complex (MHC) class I and no expression of MHC class II on the native MSCs and chondrogenic induced MSCs.
- MHC major histocompatibility complex
- the light and dark grey histograms represent the relevant isotype control staining and marker antibody staining, respectively with the corresponding percentage of mean positive cells (gated as P2) ⁇ SEM.
- MSCs mesenchymal stem cells
- PRP platelet-rich plasma
- the present invention concerns a medium and method for inducing chondrogenesis and tenogenesis in mesenchymal stem cells. It was found by the inventors that by carefully selecting the growth factors in the inducing medium as well as by the concentration range and induction time, the induction phase is made far more efficient, and the quality of the obtained induced or differentiated cells is optimised compared to cells obtained by other methodologies. Moreover, the percentage of induced cells on a total population of mesenchymal stem cells is overall higher than compared to cells obtained by the methods currently known in the art. Finally, induction of stem cells towards cell or lineage specific cells generally results in great amount of cell death or apoptosis. The latter is reduced by making use of the cell medium and methodologies according to the current invention.
- a compartment refers to one or more than one compartment.
- the value to which the modifier “about” refers is itself also specifically disclosed.
- % by weight refers to the relative weight of the respective component based on the overall weight of the formulation.
- the invention provides a cell medium for in vitro inducing chondrogenesis or tenogenesis in mesenchymal stem cells (MSCs).
- MSCs mesenchymal stem cells
- inducing or induced is to be understood as the process of activation of cell type specific genes or molecules in a multipotent or pluripotent cell, thereby driving such cell towards a more defined, specialized or differentiated cell lineage or cell type.
- chondrogenic differentiation/induction or chondrogenesis refers to the differentiation of or induction towards pluripotent or multipotent cells into cells producing an extracellular matrix close to that of cartilage or to cartilage cells.
- the chondrogenic differentiation/induction of pluripotent or multipotent cells is typically evaluated by the measurement of the pellet volume, cell morphology and matrix composition by hematoxylin-eosin (HE), safran and alcian blue staining.
- HE hematoxylin-eosin
- tenogenesis or tendogenic differentiation/induction is to be understood as the differentiation of or induction towards pluripotent or multipotent cells into tendon or ligament fibroblasts or cells close to tendon or ligament fibroblasts.
- said tenocytes are to be defined as elongated fibroblast-like cells. Their cytoplasm is stretched between the collagen fibers. They are responsible for synthesis and turnover of tendon fibers and extracellular matrix.
- said chondrocytes are to be defined as cells that produce and maintain the cartilaginous matrix, which consists mainly of collagen and proteoglycans.
- pluripotent cells refers to undifferentiated cells which can give rise to a variety of different cell lineages of the three germ layers (endoderm, mesoderm and ectoderm).
- multipotent cells and “progenitor cells” are used herein interchangeably. They refer to undifferentiated cells which can give rise to a limited number of different cell lineages, including chondrocytes. Typical multipotent cells according to the invention are mesenchymal stem cells.
- mesenchymal stem cells is to be understood as multipotent stromal cells derived or isolated from a principally mesenchymal or from stromal cells. Said mesenchymal stem cells are able to differentiate into various cell types, including but not limiting to osteoblasts, chondrocytes, tenocytes and adipocytes.
- said inducing medium comprises a glucose medium supplemented with at least one growth factor
- said growth factor is chosen from the group of fibroblast growth factors (FGF) or the group of transforming growth factors (TGF).
- FGF fibroblast growth factors
- TGF transforming growth factors
- said FGF or TGF is present in a total concentration of between 1 and 15 ng/ml. Outside these ranges, it was found that the induction and/or differentiation did not result in satisfying results, e.g. in view of obtained percentage of viable, healthy cells, which are suitable for downstream application such as regenerative therapies.
- growth factors Whilst generally higher concentrations of growth factors are chosen in the art, the inventors have found that for the specific purpose of inducing chondrogenesis or tenogenesis in mesenchymal stem cells, a specific range of between 1 to 15 ng/ml of either a TGF or an FGF is sufficient and necessary for adequate induction and differentiation of these cells. More by preference, said growth factors are present in a total concentration of between 2 and 10 ng/ml, more preferably between 3.5 and 5.5 ng/ml.
- said FGF is chosen from the group of FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10 or any combination thereof. Most preferably, said FGF is FGF-2.
- said TGF is chosen from the group of TGF ⁇ , TGF ⁇ 1, TGF ⁇ 2, TGF ⁇ 3 or any combination thereof. Most preferably, said TGF is TGF ⁇ 3.
- said TGF concentration can vary between 2 and 10 ng/ml, more preferably between 2 and 8 ng/ml, more preferably between 3.5 and 5.5 ng/ml.
- the cell medium of the current invention may further also be supplemented with other growth factors which may provide a supporting role for the tenogenic or chondrogenic induction and/or differentiation process.
- said medium may further comprise a growth factor chosen from the group of insuline-like growth factors (IGF). More by preference, said IGF is chosen from the group of IGF-2, IGF-I (also known as IGF-1), or any combination thereof. Most preferably, said IGF is IGF-I.
- said IGF is present in a concentration of between 10 and 225 ng/ml, more preferably between 60 and 200 ng/ml.
- Presence of one or more of the growth factors as described above, in their specific concentration range, are crucial for the inducing or differentiation process.
- Said cell medium also comprises a glucose medium.
- Glucose is a necessary energy source for the cells. Energy derived from glucose is stored in the form of high-energy phosphate bonds in ATP, or other nucleotide triphosphates, and as energy-rich hydrogen atoms associated with the co-enzymes NADP and NAD.
- said glucose is D-glucose.
- said concentration of the glucose in the glucose medium will preferably range from 1 g/L to as high as 4.5 g/L.
- Said glucose medium may be any culture medium known in the art which can be supplemented with glucose, such as, but not limiting to: Ames' Medium; Basal Medium Eagle (BME); BGJb Medium Fitton-Jackson Modification; Click's Medium; CMRL-1066 Medium; Dulbecco's Modified Eagle's Medium (DMEM); DMEM/Ham's Nutrient Mixture F-12 (50:50); F-12 Coon's Modification; Fischer's Medium; H-Y Medium (Hybri-Max®); Iscove's Modified Dulbecco's Medium (IMDM); McCoy's 5A Modified Medium; MCDB Media; Medium 199; Minimum Essential Medium Eagle (EMEM); NCTC Medium; Nutrient Mixture, Ham's F-10; Nutrient Mixture, Ham's F-12; Nutrient Mixture Ham's F-12 Kaighn's Modification (F12K); RPMI-1640; Serum-Free/Protein Free Hybridoma Medium; Waymouth
- the cell medium according to the current invention is further also supplemented with serum, preferably fetal serum such as fetal bovine serum or fetal calf serum (FBS or FCS).
- serum preferably fetal serum such as fetal bovine serum or fetal calf serum (FBS or FCS).
- FBS or FCS fetal bovine serum
- FCS fetal calf serum
- the cell medium may furthermore be supplemented with antibiotics and/or antimycotics, such as penicillin and/or streptomycin, or any other suitable antibiotic or antimycotic for inhibition and prohibition of the growth of bacteria, fungi and/or yeast.
- antibiotics and/or antimycotics such as penicillin and/or streptomycin, or any other suitable antibiotic or antimycotic for inhibition and prohibition of the growth of bacteria, fungi and/or yeast.
- the current invention also relates to the use of above described cell medium for inducing tenogenesis in isolated MSCs.
- said medium comprises a glucose medium, supplemented with an FGF chosen from the group of FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10 or a combination thereof, at a concentration of 5 to 10 ng/ml.
- said growth factor is FGF-2.
- said medium comprises 8 ng/ml FGF-2.
- said medium comprises 5 ng/ml FGF-2.
- said current invention is related to the use of above described cell medium for inducing chondrogenesis in isolated MSCs.
- such medium comprises a glucose medium, supplemented with a TGF chosen from the group of TGF ⁇ , TGF ⁇ 1, TGF ⁇ 2, TGF ⁇ 3 or any combination thereof, at a concentration of 5 to 10 ng/ml.
- said glucose medium comprises an IGF chosen from the group of IGF-2, IGF-I (also known as IGF-1), or any combination thereof, at a concentration between 10 and 225 ng/ml.
- the used TGF is TGF ⁇ 3, whereas the used IGF is IGF-I.
- said medium comprises 4 ng/ml TGF ⁇ 3 and 120 ng/ml IGF-I.
- the current invention also relates to a method for obtaining chondrocytes or tenocytes from isolated mesenchymal stem cells (MSCs).
- Said method comprises the step of culturing said MSCs in an inducing cell medium.
- Said inducing cell medium comprises a glucose medium supplemented with at least one growth factor, said growth factor is chosen from the group of Fibroblast Growth Factors (FGF) comprising FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10 or any combination thereof or chosen from the group of Transforming Growth Factors (TGF) TGF ⁇ , TGF ⁇ 1, TGF ⁇ 2, TGF ⁇ 3, or any combination thereof.
- FGF Fibroblast Growth Factors
- TGF Transforming Growth Factors
- said FGF or TGF is present in a total concentration of between 1 and 15 ng/ml in said medium, more preferably between 2 and 10 ng/ml.
- said medium further comprises IGF, chosen from the group of IGF-2, IGF-I (also known as IGF-1), or any combination thereof.
- said medium comprises IGF-I, preferably at a concentration between 10 and 225 ng/ml, more preferably between 50 and 225 ng/ml, even more preferably between 60 and 200 ng/ml.
- the isolated MSCs are seeded at a density of 2 to 30 ⁇ 10 3 MSCs/cm 2 , more preferably between 6 to 14 ⁇ 10 3 MSCs/cm 2 in a medium as described above.
- Cell concentration was found crucial, as too densely seeded cells tended to show heavy cell death during induction, whereas too low density results in poorly induced cells and higher risk of mutations.
- said cells are cultured for a period of 1-7 days, more preferably 12 to 72 hours in the inducing medium.
- the inventors have found that induction of cell or lineage-specific gene expression is detected within a time frame of 1 to 36 hours, from the start of the induction. The latter inducing rate differs greatly from what is known in the art. Generally, the first signs of induction of stem cells towards cell or lineage cells are seen within a far larger time span.
- the induction of the cells may be followed by screening for molecular markers which are prerequisite for the specific nature of the cell lineage.
- Molecular markers suitable for screening and following the chondrogenesis include glycosaminoglycan production, collagen type II, p63, vimentin, major histocompatibility complex, aggrecan and/or cartilage oligomeric matrix protein ( FIG. 16 ). Such expression may be analyzed by ways of (RT-)PCR ( FIG. 14 ), flow cytometry or immunochemistry. In addition, chondrogenesis may be followed by analyzing cell morphology (e.g. aided by use of HE, FIG. 13 ), or by stainings such as Alcian Blue staining or Safranin staining ( FIG. 15 ).
- MSCs induced into the chondrogenic lineage showed a more rectangular morphology.
- MSCs induced towards tenocytes are smooth muscle actin ( FIG. 4 ) and collagen type I ( FIG. 5 ).
- tenogenesis may be followed by analyzing cell morphology (e.g. aided by use of HE). Whereas native MSCs show a more stellate/spindled shaped morphology, MSCs induced into the tenogenic lineage showed a more stretched morphology and fiber orientation can be noticed.
- the MSCs useful for the current invention may be derived by any standard protocol known in the art.
- Said MSCs may be derived from for instance bone marrow, (peripheral) blood, adipose tissue, neonatal birth-associated tissues including placenta (PL), umbilical cord (blood or tissue), amnion fluid, dermis, etc.
- the MSCs are isolated according to the method as described in BE2012/0656, PCT/EP2013/070247 or PCT/EP2013/070257 which entire content is incorporated here by reference.
- Such method may comprises by preference the following steps:
- step f) minimally 2.5 ⁇ 10 5 /cm 2 cells, even more preferred between 2.5 ⁇ 10 5 /cm 2 and 5 ⁇ 10 5 /cm 2 cells are seeded.
- This number is crucial to ultimately obtain a pure and viable population MSCs at an acceptable concentration.
- the density in which the cells in step f) are seeded is essential, because planting the cells too dense will lead to massive cell death during expansion and a non-homogenous population of mesenchymal stem cells. A too low cell concentration, however, will result in little or no colony formation of mesenchymal stem cells, so that expansion is not or hardly possible, or it will take too much time. In both cases the viability of the cells will be negatively influenced.
- anti-coagulant it is meant a composition that can inhibit the coagulation of the blood.
- anticoagulants used in the present invention include EDTA or heparin.
- FIG. 3 shows a schematic representation of a 3-phase distribution of a blood sample obtained by means of centrifugation.
- the buffy coat is the middle phase B, located between the plasma-phase A and the erythrocyte-phase C.
- the buffy coat will be isolated from the other fractions and diluted by means of a suitable physiological buffer, such as for example, a phosphate, bicarbonate, or Tris buffer, preferably with a minimum ratio of 1:2.
- a suitable physiological buffer such as for example, a phosphate, bicarbonate, or Tris buffer, preferably with a minimum ratio of 1:2.
- This dilution factor is important, as lower dilution factors may lead to problems when loading the sample from step c on the density gradient, mainly due to a too heavy buffy coat fraction.
- the density gradient in step c and d of the present method is obtained by means of Percoll®. More in particular, the Percoll® will comprise a density between the de 1.08 g/ml and 1.077 g/ml.
- blood-inter-phase is to be understood as that fraction of the blood, preferably obtained by means of a density gradient, located between the bottom fraction, mainly consisting of erythrocytes and polymorph nuclear cells, and the upper fraction, mainly consisting of plasma polymorph nuclear cells.
- the blood-interphase is the source of blood mononuclear cells (BMCs) comprising monocytes, lymphocytes, and mesenchymal stem cells.
- BMCs blood mononuclear cells
- the lymphocytes are washed away at 37° C., while the monocytes die within 2 weeks in the absence of cytokines necessary to keep them alive. In this way, the MSCs are purified.
- the isolation of the mesenchymal stem cells from the blood-inter-phase is preferably done by means of centrifugation of the blood-inter-phase (after isolation of the inter-phase), after which the cell pellet is washed at least once with a suitable buffer, such as a phosphate buffer.
- the mesenchymal cells are kept at least 2 weeks in growth medium.
- the dexamethasone in the growth medium will cause the stem cells to retain their specific characteristics and keep/prevent them from differentiating.
- 1% dexamethasone is used.
- mesenchymal stem cell colonies will become visible in the culture bottles.
- a subsequent step g) at least 6 ⁇ 10 3 stem cells/cm 2 are transferred to an expansion medium containing low glucose, serum and antibiotics for the purpose of expanding the mesenchymal stem cells.
- this medium will include a maximum of 20% serum (such as FBS or FCS). Too high serum concentrations can lead to a kind of “habituation phase” of the mesenchymal stem cells to the growth factors present in the serum, which can lead to a suboptimal division of the cells in the absence of serum. This can adversely affect the cells when they are used for regenerative purposes.
- the expansion of the mesenchymal stem cells will occur in minimal five cell passages. In this way sufficient cells can be obtained.
- the cells are split at 70 to 80% confluency.
- the mesenchymal stem cells can be maintained up to 50 passages in culture. After this the risk of loss in vitality, senescence or mutation formation occurs.
- the cell population obtained by the method preferably consists of 90% mesenchymal stem cells. More preferably, it will consist of at least 95% mesenchymal stem cells, more preferably of at least 99%, most preferably 100%.
- markers specific for mesenchymal stem cells.
- markers are selected from the group consisting of vimentin, fibronectin, Ki67, or any combination thereof.
- the purity of the obtained cell populations can be analyzed, and the percentage of mesenchymal stem cells determined.
- the stem cells used in the present invention are isolated from the blood of mammals, more preferably, from peripheral blood.
- the used blood will originate from human, cat, dog or horse, most preferably equine derived.
- blood from a donor was used who was later also recipient of his isolated mesenchymal stem cells.
- blood is used from donors in which the donor is preferably of the same family, gender or race as the recipient of the mesenchymal stem cells isolated from the blood of donors.
- these donors will be tested on common current transmittable diseases or pathologies, in order to avoid the risk of horizontal transmission of these pathologies or diseases through the stem cells.
- the donor animals are kept in quarantine.
- donor horses can be, for example tested for the following pathologies: equine infectious anemia (EIA), equine rhinopneumonia (EHV-1, EHV-4), equine viral arteritis (EVA), West Nile virus (WNV), African Horse Sickness (AHS), Dourine ( Trypanosoma ), piroplasmosis, glanders (malleus, glanders), equine influenza A, Borreliosis ( Borrelia burgdorferi , Lyme disease).
- EIA equine infectious anemia
- EHV-1, EHV-4 equine rhinopneumonia
- EVA equine viral arteritis
- WNV West Nile virus
- AHS African Horse Sickness
- Dourine Trypanosoma
- the current invention also relates to a composition
- a composition comprising MSCs induced towards tenocytes or chondrocytes; tenocytes or chondrocytes, obtained from a method as described above.
- Said composition preferably comprises between 1 and 10 ⁇ 10 6 cells/ml, preferably between 2 and 5 ⁇ 10 6 cells/ml.
- Said cells are by preference suspended in a suitable cell medium, such as for instance DMEM.
- a suitable amount of cryoprotectant is added.
- cryoprotectant may for instance be DMSO.
- said DMSO is added in a volume of 10%.
- Cells are preferably kept at ⁇ 80° C. prior to use.
- Cells for freezing are obtained after an induction time of typically between 1 to 36 hours. Cultured cells are washed with a saline buffer such as PBS and treated with a solution comprising trypsin and/or EDTA for detaching the cells, preferably at a temperature of 37° C. After the cells have detached, trypsin action is inactivated by adding warm (37° C.) medium to the cells. The cell solution is subsequently centrifuged to obtain a cell pellet. Solution is preferably centrifuged at 300 G for a period between 5 and 10 minutes, more preferably 8 minutes, at room temperature. Supernatants is subsequently removed and cells are re-suspended towards the required cell concentration.
- composition is formulated for intravenous, intra-articular, intramuscular, intra-lesional administration to mammals. These modes of administration will depend heavily on the desired application of stem cells and/or their differentiated form.
- compositions based on hyaluronic acid can be used with components selected from the group consisting of platelet-rich plasma (PRP), hyaluronic acid, compositions based on hyaluronic acid, glycosaminoglycans, or compositions based on glycosaminoglycans.
- PRP platelet-rich plasma
- hyaluronic acid hyaluronic acid
- glycosaminoglycans based on glycosaminoglycans
- glycosaminoglycans can be used with components selected from the group consisting of platelet-rich plasma (PRP), hyaluronic acid, compositions based on hyaluronic acid, glycosaminoglycans, or compositions based on glycosaminoglycans.
- PRP for example, a substance rich in growth factors, stimulate the stem cells after implantation.
- both the stem cells and PRP are harvested from the same donors are for compatibility reasons.
- Carrier substances can also be used to counteract gravity: stem cells follow the law of gravity and therefore have difficulties reaching higher lesions without a carrier in which they can migrate.
- the carrier substances themselves also have beneficial effects on the pathological environment in which they contribute to the tissue repair itself and also provide a good stem cell niche to help differentiation of the cells in this area.
- hyaluronic acid, glycosaminoglycans or compositions on this basis include OSTENIL®, OSTENIL® +, Adant® and Adequan®.
- composition according to the present invention has very broad applicability.
- composition is suitable for the following purposes:
- a subject benefits from administering the composition to said subject.
- the subject may include a horse, cat, dog or human.
- a method for administering a composition according to the present invention to a subject may include the following steps:
- the cell diameter of the injection needle is crucial in this respect, in order to avoid damage to the cells. Defrosting the composition can be accomplished by thawing in a hot water bath or in the palm of one's hand or by any other method within the temperature limits.
- the composition is administered within 2 minutes after thawing, in order to safeguard the vitality of the composition.
- Cells were seeded at a concentration of 6 to 14 ⁇ 10 3 MSCs/cm 2 in cell inducing medium. The following media were used:
- cartilage gene expression (Aggrecan (ACAN), Cartilage Oligomeric Matrix Protein (COMP) and Collagen 2A (COLL 2A)
- FIG. 1 A RT-PCR results.
- tendon gene increase Collagen I and III
- cartilage gene decrease Collagen II was noticed within a time span of 1-7 days (depending on the experiment) (see FIG. 1 B ).
- Example 3 Tenogenic Potential from Human AT-MSCs, UC-MSCs or BM-MSCs
- the inventors furthermore checked the difference in tenogenic “inducive” potential between MSCs derived from human adipose tissue (AT), umbilical cord blood (UC) or bone-marrow derived MSCs (BM).
- AT human adipose tissue
- UC umbilical cord blood
- BM bone-marrow derived MSCs
- AT human adipose tissue
- UC umbilical cord blood
- BM MSCs bone-marrow derived MSCs
- the acute phase consists of an increase in collagen type III, which will be replaced by the more elastic collagen type I.
- collagen type III which will be replaced by the more elastic collagen type I.
- tenogenic induced UC MSCs in humans or blood-derived MSCs it is possible to mimic this increase in a faster rate, while avoiding a too long remodeling phase, because of the higher amount of collagen type I.
- MSCs Mesenchymal Stem Cells
- PBMCs peripheral blood mononuclear cells
- the cells were trypsinized with 0.25% trypsin-EDTA and subcultured in tenogenic inducing medium (DMEM LG+20% FCS+1% P/S+FGF( ⁇ 2) (5 ng/ml).) for 3 days.
- DMEM LG+20% FCS+1% P/S+FGF( ⁇ 2) 5 ng/ml.
- the cells were trypsinized and resuspended in 1 ml of DMEM low glucose with 10% of dimethyl sulfoxide (DMSO, Sigma). At this point the cells were frozen overnight in isopropanol at ⁇ 80° C. The samples were then stored in ⁇ 80° C. and shipped on dry-ice before clinical application.
- peripheral blood was taken in a citrate phosphate dextrose adenine-1 (CPDA-1) single blood bag (Terumo®) for platelet-rich plasma (PRP) preparation.
- CPDA-1 citrate phosphate dextrose adenine-1
- PRP platelet-rich plasma
- Immunohistochemistry was performed to evaluate the expression of markers present on tenogenic induced MSCs.
- Cells were fixed for 10 minutes with 4% PF and permeabilized for 2 minutes with 0.1% Triton X at room temperature. Subsequently, cells were incubated with hydrogen peroxide (0.03%) for 5 minutes at room temperature and after washing with PBS, incubated for 2 hours at room temperature with the primary mouse IgG2a monoclonal anti-human smooth muscle actin (SMA) antibody (Dako, 1:200) and the rabbit IgG polyclonal anti-human collagen type IA2 (Col IA2) antibody (Abcam, 1:100).
- SMA monoclonal anti-human smooth muscle actin
- the tenocytes (1 ml) and PRP (1 ml) were aspirated in the same syringe and intralesionally administered by means of ultrasound guidance.
- Clinical lameness was also noticeable in most of the cases.
- the horses were closely monitored for 1 week by means of a daily examination of their tendons and by observing possible adverse effects or hypersensitivity reactions (wheal formation, sweating, strong respirations or even fever).
- the tendons were evaluated at approximately 6 weeks post injection through ultrasound imaging and by lameness evaluation.
- Four veterinary practitioners were asked to give a score between 0 and 5 for their ultrasound images at approximately 6 weeks after the treatment.
- the horses were initially treated conservatively for 5 days with non-steroidal anti-inflammatory drugs (NSAIDs), resting, cooling and a compressive bandage in order to reduce the swelling of the region and obtain optimal conditions for the intralesional injection.
- NSAIDs non-steroidal anti-inflammatory drugs
- an intralesional injection of PRP or a tenocyte induced cell composition according to the current invention was randomly assigned to each horse and performed using ultrasound guidance. All 8 horses were immobilized (box rest) for 3 weeks, followed by daily walking exercises for 5 to 10 minutes for another 3 weeks. The first follow-up was planned 6 weeks after the injection. A second clinical and ultrasonographic examination was performed at 4 months after treatment.
- the horses were re-evaluated clinically and ultrasonographically 6 weeks and 4 months after the injection with PRP or the cell composition.
- the clinical examination consisted of a visual inspection, palpation for the presence of swelling and/or heat, general inspection of the patient and a concise lameness evaluation.
- a thorough ultrasound examination was performed at the lesion site.
- the ease, safety and non-invasiveness of this method permitted not only a morphologic in vivo evaluation of the lesions, but, more importantly an observation over time. Thanks to the technological advances and decreasing equipment cost, this imaging modality is very useful and readily available in practice. Two veterinary practitioners were asked to give a score between 0 and 5 for the ultrasound images of all the patients.
- the scoring system was adapted from a previous study about superficial digital flexor tendinitis and desmitis of the suspensory ligament by Broeckx et al, 2012.
- the threshold for improvement after successful conservative therapy was set at maximal 40% at 6 weeks and 60% at 4 months after conservative treatment.
- each sample contained approximately 200 ⁇ 10 6 platelets per ml and was frozen and stored at 1 ml per sample in a ⁇ 80° C. ultralow temperature freezer (Haier, Elscolab) before clinical application.
- bacteriological, fungal and yeast examinations were performed. Obviously, only the samples that were negative for the microbiological examinations were released for clinical use.
- a liquid form of PRP was used. In this regard, we were able to compare the tenocyte induced composition with PRP using the same treatment protocol and similar carrier fluids.
- FIG. 11 represents the ultrasound images of 3 patients before and 6 weeks after treatment with tenocyte induced cell composition. A considerable filling of the lesions could be noticed in all cases. Still, the lesions were not completely filled, and therefore, the patients were advised to continue and increase the walking exercise for 3 more weeks, followed by trotting exercise until 4 months after the treatment.
- Chondrogenic induction medium comprised of DMEM Low Glucose, 20% FCS, 1% AB/AM and 4 ng/ml TGF- ⁇ 3+120 ng/ml IGF-I.
- chondrogenic induced cells were trypsinized, resuspended in 1 ml of DMEM low glucose with 10% of dimethyl sulfoxide (DMSO, Sigma) and frozen before being shipped on dry-ice for clinical application.
- DMSO dimethyl sulfoxide
- peripheral blood 300 ml of peripheral blood was taken in a citrate phosphate dextrose adenine-1 (CPDA-1) single blood bag (Terumo®) for platelet-rich plasma (PRP) preparation. From this donor horse, 30 samples of 1 ml PRP were prepared. Each sample contained approximately 200 ⁇ 10 6 platelets and was frozen and stored at ⁇ 80° C. before clinical application.
- CPDA-1 citrate phosphate dextrose adenine-1
- PRP platelet-rich plasma
- Hematoxylin (HE), Crystal Violet (CV), Alcian Blue (AB) and Safranin O (SO) staining were performed on MSCs and chondrogenic-induced MSCs, as indicated by the manufacturer. Both HE and CV staining were carried out in order to visualize the cell morphology and cellular organization. Furthermore, AB and SO staining were performed to give an indication of the presence of acid polysaccharides, such as glycosaminoglycans in cartilage-like structures.
- Immunocytochemistry was performed to evaluate the expression of collagen type II (Col II), Ki67 (proliferation marker), p63 (tumor suppression gene) and vimentin (mesenchymal cell marker) on native MSCs and chondrogenic-induced MSCs after trypsinization and cytospin preparation at 700 rpm for 4 minutes. Cells were fixed for 10 minutes with 4% PF and permeabilized for 2 minutes with 0.1% Triton X at room temperature.
- cells were incubated with hydrogen peroxide (0.03%) for 5 minutes at room temperature and after washing with PBS, incubated for 30 minutes at room temperature with the primary rabbit IgG polyclonal antibodies recognizing: Col IIA1 (1:50), Ki67 (1:200) and p63 (1:100) and mouse IgG1 monoclonal anti-vimentin (1:100) (all from Abcam).
- primary rabbit IgG polyclonal antibodies recognizing: Col IIA1 (1:50), Ki67 (1:200) and p63 (1:100) and mouse IgG1 monoclonal anti-vimentin (1:100) (all from Abcam).
- secondary ready-to-use goat anti-mouse and anti-rabbit peroxidase (PO)-linked antibodies DO
- DAB 3,3′-diaminobenzidine
- MHC major histocompatibility complex
- 400,000 cells were used and labeled with the following primary antibodies: mouse anti-horse MHC class I IgG2a (Washington State University, 1:50) and mouse anti-horse MHC class II IgG1 (Abd Serotec, 1:50).
- Cells were incubated with the primary antibodies for 15 minutes on ice in the dark and washed twice in washing buffer, consisting of DMEM with 1% bovine serum albumin (BSA).
- BSA bovine serum albumin
- a secondary rabbit anti-mouse-FITC (Abcam, 1:100) antibody was used to identify positive cells after 15 minutes of incubation on ice in the dark. Finally, all cells were washed three times in washing buffer and at least 10,000 cells were evaluated using a fluorescence activated cell sorter (FACS) Canto flow cytometer (Becton Dickinson Immunocytometry systems) equipped with a 488 nm solid state and a 633 nm HeNe laser, and these data were subsequently analysed with the FACS Diva software. All analyses were based on (i) autofluorescence and (ii) control cells incubated with isotype-specific IgG's, in order to establish the background signal. All isotypes were matched to the immunoglobulin subtype and used at the same protein concentration as the corresponding antibodies.
- FACS fluorescence activated cell sorter
- Equine MSCs in passage 3 were seeded in T25 flasks at a density of 8,000 MSCs/cm2 with either expansion medium (minus the chondrogenic inducing factors) or chondrogenic induction medium for 30 hours. After treatment, cells were lysed in 2 ml of Trizol (Invitrogen) and the lysate was separated into aqueous and organic phases by chloroform separation (300 ⁇ l, Sigma-Aldrich). The aqueous phase was recovered after centrifugation and total RNA was precipitated by using equal volumes of isopropanol.
- RNAse free water was washed with 75% EtOH once and then solubilized with 25 ⁇ l of RNAse free water and quantified on the Nanodrop Lite (Fisher Scientific) before reverse transcribing 1 ⁇ g of RNA, using the TaqMan Reverse Transcription Reagents Kit (Life Technologies).
- MSCs mesenchymal stem cells
- PRP native MSCs
- PRP native MSCs plus PRP
- chondrogenic-induced MSCs plus PRP Combination 2
- horses were randomly assigned to one of the two combination therapies. After thawing, both MSCs and PRP were aspirated in the same syringe (for combination groups) and administered intra-articulary. After the treatment, the horses were closely monitored for 1 week by means of a daily examination of the injected joint and by observing the occurrence of possible adverse effects or hypersensitivity reactions (wheal formation, sweating, strong respirations or even fever).
- the average of the evolution scores at 6 and 12 weeks represented the early evolution score
- the average of the evolution scores at 6 and 12 months represented the late evolution score.
- the early and late evolution scores are compared between the group receiving both MSCs (either native or induced) and PRP and the group receiving only MSCs on the one hand or receiving only PRP on the other hand, using the Wilcoxon signed rank sum test at the 5% significance level.
- the chondrogenic-induced MSCs are compared with native MSCs only for the earliest evolution score (i.e. at 6 weeks) equally using the Wilcoxon signed rank sum test at the 5% significance level.
- MSCs Mesenchymal Stem Cells
- the first spindle shaped cells were noticed after 17 days in culture and were isolated at 21 days at approximately 60% confluency.
- MHC major histocompatibility complex
- the clinical evolution score of each patient per treatment group can be found in Table 4.
- Table 4 An overview of the average evolution scores after each treatment is presented in FIG. 18 A .
- the results of the different treatments with respect to the early and late evolution scores can be found in Table 5.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rehabilitation Therapy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The current invention concerns a composition for treating trauma in a subject, where the composition includes isolated mesenchymal stem cells (MSCs), wherein the MSCs are tenogenic-induced and/or chondrogenic-induced, and where the trauma is tendon trauma, traumas of the ligaments, or trauma of cartilage.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/689,898, filed Nov. 20, 2019, which is a division of U.S. patent application Ser. No. 15/038,172, now U.S. Pat. No. 10,801,014, filed Oct. 13, 2020, which is a national stage application of PCT/EP2013/075782, filed Dec. 6, 2013, which are all hereby incorporated by reference in their entirety.
- The present invention relates to the field of methods and compositions for directing mesenchymal progenitor cells cultivated in vitro to differentiate into specific cell lineage pathways, and particularly to such directed lineage induction prior to, or at the time of, their implantation into a recipient or host for the therapeutic treatment of pathologic conditions in humans and other species.
- Mesenchymal stem cells (MSCs) are the formative pluripotent blast or embryonic-like cells found in bone marrow, blood, dermis, and periosteum that are capable of differentiating into specific types of mesenchymal or connective tissues including adipose, osseous, cartilaginous, elastic, muscular, and fibrous connective tissues. The specific differentiation pathway which these cells enter depends upon various influences from mechanical influences and/or endogenous bioactive factors, such as growth factors, cytokines, and/or local micro-environmental conditions established by host tissues.
- Damage to the articular surfaces of synovial joints, or tendon and ligament lesions can arise from trauma, from diseases (e.g. osteoarthritis), and as a result of the aging process. To date, most prescribed therapies include conservative treatments such as administration of NSAIDs, corticoid treatment, surgical treatments, bandaging, etc. However, the latter are often found to be ineffective and time-consuming.
- It has been proposed that treatment of damage to chondrogenic and tenogenic tissue could be repaired by implanting autologous cells (e.g. tenocytes or chondrocytes). Articular cartilage for instance is created and maintained during prenatal and postnatal growth by mesenchymal cells that have differentiated into articular chondrocytes. Individuals may lose the ability to repair major synovial defects as they mature because their joints lack sufficient numbers of properly-differentiated cells to regenerate articular cartilage. Thus, there has been a great deal of interest in the hypothesis that damaged joint surfaces may be repaired by implanting autologous cells that will reconstitute a suitable extracellular matrix.
- WO 1998 032 333 describes a process for producing chondrocytes from mesenchymal stem cells thereby using of a medium supplemented with growth factors from the transforming growth factor-β super-family.
- WO 2010 007 551 discloses a method for inducing tenogenesis whereby a cell medium comprising bon morphogenetic proteins.
- Although the autologous approach is promising, a recurrent problem in the art is the poor quality and compatibility of the cells used, hence leading to poor regenerative results and ineffective treatment. Often this is due to poorly induced or differentiated cells, which on its turn is a direct cause of an inadequate inducing methodology and inducing medium.
- Thus, there is a continuing need for improved inducing methodology of stem cells towards tenocytes and chondrocytes, which can be used for regenerative therapy.
- The present invention provides for a cell medium according to
claim 1 and use of such cell medium for inducing chondrogenesis or tenogenesis according toclaim - The cell medium and methodology according to the current invention provides for an optimized manner of inducing tenogenesis or chondrogenesis in stem cells, obtaining a higher percentage of correctly induced cells. Furthermore, the cells according to the current invention are suitable for application in regenerative treatment.
-
FIG. 1A shows marker expression of chondrogenic specific markers in chondrogenic induced MSCs according to the current invention.FIG. 1B shows induction of tenogenic specific markers in tenogenic induced MSCs. -
FIG. 2A shows the tenogenic potential of human MSCs derived from adipose tissue (AT). -
FIG. 2B shows the tenogenic potential of human MSCs derived from umbilical cord blood (UC). -
FIG. 2C shows the tenogenic potential of human MSCs derived from bone-marrow derived MSCs (BM). -
FIG. 3 shows representative light microscopic images of peripheral blood (PB)-derived mesenchymal stem cells (MSCs) in their undifferentiated state and after tenogenic induction. The typical tenogenic morphology and longitudinal orientation could be noticed after induction. -
FIG. 4 shows immunohistochemistry data which revealed that the tenogenic induced mesenchymal stem cells (MSCs) according to an embodiment of the current invention were all positive for smooth muscle actin (SMA).FIG. 5 shows immunohistochemistry data which revealed that some (arrows) of the tenogenic induced mesenchymal stem cells (MSCs) according to an embodiment of the current invention were positive for collagen type I. The typical tenogenic morphology and longitudinal orientation can be noticed on the images. -
FIG. 6 shows histograms representing the number of patients and the different scores they received from the veterinary practitioners (0-5) at approximately 6 weeks after treatment of their superficial digital flexor tendon (SDFT) or suspensory ligament (SL). A score of 0 corresponded with 0% improvement or no ultrasonic improvement and 5 with 100% improvement or no ultrasonic abnormalities. Except for 1, all the patients (n=25) received at least a score 3 (60% improvement or better ultrasonic improvement than after successful conservative therapy). -
FIG. 7 shows a longitudinal (left side) and transversal (right side) ultrasound image of a lesion (white circle) in the lateral edge of the superficial digital flexor tendon (SDFT) of a horse. At 39 days after treatment with a tenogenic induced composition according to the current invention and PRP, ascore 4 was given, because the fiber orientation was not completed yet on the longitudinal image (black circle). -
FIG. 8 shows an ultrasound image of a lesion (white circle) in the lateral branch of the suspensory ligament (SL) of a horse. At 35 days after the treatment with a tenogenic induced composition according to an embodiment of the current invention and PRP, ascore 4 was given, because, although the fiber orientation was completed, there were still some small hypoechogenic zones (black circle). The black arrow indicates a zone of calcification. -
FIG. 9 shows representative light microscopic images at a 20× magnification of equine peripheral blood (PB)-derived mesenchymal stem cells (MSCs) in their undifferentiated state and after tenogenic induction according to an embodiment of the current invention. In contrast to the spindle shaped morphology of the MSCs, the typical lengthened tenogenic morphology and longitudinal orientation could be noticed in tenogenic induced cells. -
FIG. 10 represents a timeline of a treatment and follow-up protocol used in the present study at different time points (T). -
FIG. 11 shows histograms which represent the number of patients and the different scores they received from the veterinary practitioners (0-5) at approximately 6 weeks and 4 months after treatment of their accessory ligament of the deep digital flexor tendon (ALDDFT). At 6 weeks after treatment with platelet-rich plasma (PRP), all 4 patients (light grey) received ascore 2/5. At the same time point, all 4 a tenogenic induced treated patients (dark grey) received ascore 4/5. At 4 months after PRP treatment, all the patients received ascore 3/5. Although 1 of the tenogenic induced treated patients received the same score, the other 3 patients received ascore 5/5. -
FIG. 12 shows transversal (T) and longitudinal (L) ultrasound images of a lesion (white circle) in accessory ligament of the deep digital flexor tendon (ALDDFT) in 3 horses (H) before (left column) and 6 weeks after (right column) treatment with tenogenic induced allogenic mesenchymal stem cells (TC). At approximately 6 weeks after the treatment, ascore 4 was given to all the treated ALDDFTs, because, although the fiber orientation was completed, there were still some small hypo-echoic zones. -
FIG. 13 shows representative images of peripheral blood (PB)-derived mesenchymal stem cells (MSCs) in their undifferentiated state (panels A & C) and chondrogenic induced according to an embodiment of the current invention (panels B & D) after Hematoxylin (panels A & B) and Crystal Violet (panels C & D) stainings. The typical chondrogenic morphology and lacune formation (black arrow) can be noticed after induction. Scale bars represent 50 μm. -
FIG. 14 shows the results of RT-PCR for the gene expression of collagen (Col) type II, aggrecan and cartilage oligomeric matrix protein (COMP) in the native MSCs (Control) and chondrogenic induced MSCs (Induced) according to the current invention. Values are given as the mean of three measurements±SEM. -
FIG. 15 shows representative images of peripheral blood (PB)-derived mesenchymal stem cells (MSCs) in their undifferentiated state (A & C) and chondrogenic induced (B & D) after Safranin O (A & B) and Alcian Blue (C & D) stainings. Glycosaminoglycan production (black arrows) can be noticed after induction. Scale bars represent 50 μm. -
FIG. 16 shows results of immunocytochemistry on cytospins using Ki67 (A), collagen (Col) type II (B), vimentin (C) and p63 (D). Native mesenchymal stem cells (MSCs) were negative for p63 and positive for Ki67, Col II and vimentin, whereas chondrogenic induced MSCs were positive for p63, Col II and vimentin and slightly positive for Ki67. Arrows indicate a decreased signal for Ki67 in some chondrogenic induced MSCs. The relevant isotype controls were negative. Scale bar represents 25 μm. -
FIG. 17 shows flow cytometic experiments which confirmed a very low expression of major histocompatibility complex (MHC) class I and no expression of MHC class II on the native MSCs and chondrogenic induced MSCs. The light and dark grey histograms represent the relevant isotype control staining and marker antibody staining, respectively with the corresponding percentage of mean positive cells (gated as P2)±SEM. -
FIG. 18 shows the Clinical evolution scores of the different treatments at the early and late time point in the first study (A). Values are given as the mean±SEM. Diagrams represent the clinical evolution scores of 30 horses treated with native mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) (Combination 1, n=15) or chondrogenic induced MSCs and PRP (Combination 2, n=15) in the second study (B). - The present invention concerns a medium and method for inducing chondrogenesis and tenogenesis in mesenchymal stem cells. It was found by the inventors that by carefully selecting the growth factors in the inducing medium as well as by the concentration range and induction time, the induction phase is made far more efficient, and the quality of the obtained induced or differentiated cells is optimised compared to cells obtained by other methodologies. Moreover, the percentage of induced cells on a total population of mesenchymal stem cells is overall higher than compared to cells obtained by the methods currently known in the art. Finally, induction of stem cells towards cell or lineage specific cells generally results in great amount of cell death or apoptosis. The latter is reduced by making use of the cell medium and methodologies according to the current invention.
- Unless otherwise defined, all terms used in disclosing the invention, including technical and scientific terms, have the meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. By means of further guidance, term definitions are included to better appreciate the teaching of the present invention.
- As used herein, the following terms have the following meanings:
- “A”, “an”, and “the” as used herein refers to both singular and plural referents unless the context clearly dictates otherwise. By way of example, “a compartment” refers to one or more than one compartment.
- “About” as used herein referring to a measurable value such as a parameter, an amount, a temporal duration, and the like, is meant to encompass variations of +/−20% or less, preferably +/−10% or less, more preferably +/−5% or less, even more preferably +/−1% or less, and still more preferably +/−0.1% or less of and from the specified value, in so far such variations are appropriate to perform in the disclosed invention. However, it is to be understood that the value to which the modifier “about” refers is itself also specifically disclosed.
- “Comprise,” “comprising,” and “comprises” and “comprised of” as used herein are synonymous with “include”, “including”, “includes” or “contain”, “containing”, “contains” and are inclusive or open-ended terms that specifies the presence of what follows e.g. component and do not exclude or preclude the presence of additional, non-recited components, features, element, members, steps, known in the art or disclosed therein.
- The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within that range, as well as the recited endpoints.
- The expression “% by weight” (weight percent), here and throughout the description unless otherwise defined, refers to the relative weight of the respective component based on the overall weight of the formulation.
- In a first aspect, the invention provides a cell medium for in vitro inducing chondrogenesis or tenogenesis in mesenchymal stem cells (MSCs).
- The term “inducing or induced” is to be understood as the process of activation of cell type specific genes or molecules in a multipotent or pluripotent cell, thereby driving such cell towards a more defined, specialized or differentiated cell lineage or cell type.
- The term “chondrogenic differentiation/induction or chondrogenesis”, as used herein, refers to the differentiation of or induction towards pluripotent or multipotent cells into cells producing an extracellular matrix close to that of cartilage or to cartilage cells. The chondrogenic differentiation/induction of pluripotent or multipotent cells is typically evaluated by the measurement of the pellet volume, cell morphology and matrix composition by hematoxylin-eosin (HE), safran and alcian blue staining.
- The term “tenogenesis or tendogenic differentiation/induction” is to be understood as the differentiation of or induction towards pluripotent or multipotent cells into tendon or ligament fibroblasts or cells close to tendon or ligament fibroblasts.
- For the purpose of the current invention, said tenocytes are to be defined as elongated fibroblast-like cells. Their cytoplasm is stretched between the collagen fibers. They are responsible for synthesis and turnover of tendon fibers and extracellular matrix.
- For the purpose of the current invention, said chondrocytes are to be defined as cells that produce and maintain the cartilaginous matrix, which consists mainly of collagen and proteoglycans.
- The term “pluripotent cells”, as used herein, refers to undifferentiated cells which can give rise to a variety of different cell lineages of the three germ layers (endoderm, mesoderm and ectoderm).
- The terms “multipotent cells” and “progenitor cells” are used herein interchangeably. They refer to undifferentiated cells which can give rise to a limited number of different cell lineages, including chondrocytes. Typical multipotent cells according to the invention are mesenchymal stem cells.
- The term “mesenchymal stem cells” is to be understood as multipotent stromal cells derived or isolated from a principally mesenchymal or from stromal cells. Said mesenchymal stem cells are able to differentiate into various cell types, including but not limiting to osteoblasts, chondrocytes, tenocytes and adipocytes.
- By preference, said inducing medium comprises a glucose medium supplemented with at least one growth factor, said growth factor is chosen from the group of fibroblast growth factors (FGF) or the group of transforming growth factors (TGF). In a preferred embodiment, said FGF or TGF is present in a total concentration of between 1 and 15 ng/ml. Outside these ranges, it was found that the induction and/or differentiation did not result in satisfying results, e.g. in view of obtained percentage of viable, healthy cells, which are suitable for downstream application such as regenerative therapies.
- Whilst generally higher concentrations of growth factors are chosen in the art, the inventors have found that for the specific purpose of inducing chondrogenesis or tenogenesis in mesenchymal stem cells, a specific range of between 1 to 15 ng/ml of either a TGF or an FGF is sufficient and necessary for adequate induction and differentiation of these cells. More by preference, said growth factors are present in a total concentration of between 2 and 10 ng/ml, more preferably between 3.5 and 5.5 ng/ml.
- In a further embodiment, said FGF is chosen from the group of FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10 or any combination thereof. Most preferably, said FGF is FGF-2.
- In another embodiment, said TGF is chosen from the group of TGFα, TGFβ1, TGFβ2, TGFβ3 or any combination thereof. Most preferably, said TGF is TGF β3. By preference, said TGF concentration can vary between 2 and 10 ng/ml, more preferably between 2 and 8 ng/ml, more preferably between 3.5 and 5.5 ng/ml.
- The cell medium of the current invention may further also be supplemented with other growth factors which may provide a supporting role for the tenogenic or chondrogenic induction and/or differentiation process. By preference, said medium may further comprise a growth factor chosen from the group of insuline-like growth factors (IGF). More by preference, said IGF is chosen from the group of IGF-2, IGF-I (also known as IGF-1), or any combination thereof. Most preferably, said IGF is IGF-I.
- In a preferred embodiment, said IGF is present in a concentration of between 10 and 225 ng/ml, more preferably between 60 and 200 ng/ml.
- Presence of one or more of the growth factors as described above, in their specific concentration range, are crucial for the inducing or differentiation process.
- Said cell medium also comprises a glucose medium. Glucose is a necessary energy source for the cells. Energy derived from glucose is stored in the form of high-energy phosphate bonds in ATP, or other nucleotide triphosphates, and as energy-rich hydrogen atoms associated with the co-enzymes NADP and NAD. By preference, said glucose is D-glucose. In a further embodiment, said concentration of the glucose in the glucose medium will preferably range from 1 g/L to as high as 4.5 g/L.
- Said glucose medium may be any culture medium known in the art which can be supplemented with glucose, such as, but not limiting to: Ames' Medium; Basal Medium Eagle (BME); BGJb Medium Fitton-Jackson Modification; Click's Medium; CMRL-1066 Medium; Dulbecco's Modified Eagle's Medium (DMEM); DMEM/Ham's Nutrient Mixture F-12 (50:50); F-12 Coon's Modification; Fischer's Medium; H-Y Medium (Hybri-Max®); Iscove's Modified Dulbecco's Medium (IMDM); McCoy's 5A Modified Medium; MCDB Media; Medium 199; Minimum Essential Medium Eagle (EMEM); NCTC Medium; Nutrient Mixture, Ham's F-10; Nutrient Mixture, Ham's F-12; Nutrient Mixture Ham's F-12 Kaighn's Modification (F12K); RPMI-1640; Serum-Free/Protein Free Hybridoma Medium; Waymouth Medium MB; Williams Medium E and various proprietary media.
- The cell medium according to the current invention is further also supplemented with serum, preferably fetal serum such as fetal bovine serum or fetal calf serum (FBS or FCS). By preference, said serum is present in between 10% and 30% of the total volume of the cell medium. The current concentration was found to be important for the conservation of the stability the growth factor(s) in the medium.
- The cell medium may furthermore be supplemented with antibiotics and/or antimycotics, such as penicillin and/or streptomycin, or any other suitable antibiotic or antimycotic for inhibition and prohibition of the growth of bacteria, fungi and/or yeast.
- In a further aspect, the current invention also relates to the use of above described cell medium for inducing tenogenesis in isolated MSCs. By preference, said medium comprises a glucose medium, supplemented with an FGF chosen from the group of FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10 or a combination thereof, at a concentration of 5 to 10 ng/ml. Most preferably, said growth factor is FGF-2. In a further preferred embodiment, said medium comprises 8 ng/ml FGF-2. In another preferred embodiment, said medium comprises 5 ng/ml FGF-2.
- In a third aspect, said current invention is related to the use of above described cell medium for inducing chondrogenesis in isolated MSCs. By preference, such medium comprises a glucose medium, supplemented with a TGF chosen from the group of TGFα, TGFβ1, TGFβ2, TGFβ3 or any combination thereof, at a concentration of 5 to 10 ng/ml. In a further embodiment, said glucose medium comprises an IGF chosen from the group of IGF-2, IGF-I (also known as IGF-1), or any combination thereof, at a concentration between 10 and 225 ng/ml. By preference, the used TGF is TGFβ3, whereas the used IGF is IGF-I. In a most preferred embodiment, said medium comprises 4 ng/ml TGFβ3 and 120 ng/ml IGF-I.
- In a fourth aspect, the current invention also relates to a method for obtaining chondrocytes or tenocytes from isolated mesenchymal stem cells (MSCs). Said method comprises the step of culturing said MSCs in an inducing cell medium. Said inducing cell medium comprises a glucose medium supplemented with at least one growth factor, said growth factor is chosen from the group of Fibroblast Growth Factors (FGF) comprising FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10 or any combination thereof or chosen from the group of Transforming Growth Factors (TGF) TGFα, TGFβ1, TGFβ2, TGFβ3, or any combination thereof. In a preferred embodiment, said FGF or TGF is present in a total concentration of between 1 and 15 ng/ml in said medium, more preferably between 2 and 10 ng/ml.
- In a further embodiment, said medium further comprises IGF, chosen from the group of IGF-2, IGF-I (also known as IGF-1), or any combination thereof. By preference, said medium comprises IGF-I, preferably at a concentration between 10 and 225 ng/ml, more preferably between 50 and 225 ng/ml, even more preferably between 60 and 200 ng/ml.
- The isolated MSCs are seeded at a density of 2 to 30×103 MSCs/cm2, more preferably between 6 to 14×103 MSCs/cm2 in a medium as described above. Cell concentration was found crucial, as too densely seeded cells tended to show heavy cell death during induction, whereas too low density results in poorly induced cells and higher risk of mutations.
- By preference, said cells are cultured for a period of 1-7 days, more preferably 12 to 72 hours in the inducing medium. The inventors have found that induction of cell or lineage-specific gene expression is detected within a time frame of 1 to 36 hours, from the start of the induction. The latter inducing rate differs greatly from what is known in the art. Generally, the first signs of induction of stem cells towards cell or lineage cells are seen within a far larger time span.
- The induction of the cells may be followed by screening for molecular markers which are prerequisite for the specific nature of the cell lineage.
- Molecular markers suitable for screening and following the chondrogenesis include glycosaminoglycan production, collagen type II, p63, vimentin, major histocompatibility complex, aggrecan and/or cartilage oligomeric matrix protein (
FIG. 16 ). Such expression may be analyzed by ways of (RT-)PCR (FIG. 14 ), flow cytometry or immunochemistry. In addition, chondrogenesis may be followed by analyzing cell morphology (e.g. aided by use of HE,FIG. 13 ), or by stainings such as Alcian Blue staining or Safranin staining (FIG. 15 ). - Whereas native MSCs show a more stellate/spindled shaped morphology, MSCs induced into the chondrogenic lineage showed a more rectangular morphology.
- MSCs induced towards tenocytes are smooth muscle actin (
FIG. 4 ) and collagen type I (FIG. 5 ). In addition, tenogenesis may be followed by analyzing cell morphology (e.g. aided by use of HE). Whereas native MSCs show a more stellate/spindled shaped morphology, MSCs induced into the tenogenic lineage showed a more stretched morphology and fiber orientation can be noticed. - The MSCs useful for the current invention may be derived by any standard protocol known in the art. Said MSCs may be derived from for instance bone marrow, (peripheral) blood, adipose tissue, neonatal birth-associated tissues including placenta (PL), umbilical cord (blood or tissue), amnion fluid, dermis, etc.
- In one embodiment, the MSCs are isolated according to the method as described in BE2012/0656, PCT/EP2013/070247 or PCT/EP2013/070257 which entire content is incorporated here by reference.
- More specifically, such method may comprises by preference the following steps:
-
- a) the collection of one or more blood samples from donors, in a sample vial, coated with an anti-coagulant;
- b) centrifuging the blood samples to obtain a 3-phase distribution, consisting of a plasma-phase, buffy coat, and erythrocytes phase;
- c) collecting the buffy coat and loading it on a density gradient;
- d) collecting of the blood-inter-phase obtained from the density gradient of step c);
- e) isolating of mesenchymal stem cells from the blood-inter-phase by centrifugation;
- f) seeding at least 2.5×105/cm2 mesenchymal stem cells in culture and keeping them in a low glucose growth medium supplemented with dexamethasone, antibiotics and serum.
- Preferably, in step f) minimally 2.5×105/cm2 cells, even more preferred between 2.5×105/cm2 and 5×105/cm2 cells are seeded. This number is crucial to ultimately obtain a pure and viable population MSCs at an acceptable concentration. The density in which the cells in step f) are seeded, is essential, because planting the cells too dense will lead to massive cell death during expansion and a non-homogenous population of mesenchymal stem cells. A too low cell concentration, however, will result in little or no colony formation of mesenchymal stem cells, so that expansion is not or hardly possible, or it will take too much time. In both cases the viability of the cells will be negatively influenced.
- By the term anti-coagulant, it is meant a composition that can inhibit the coagulation of the blood. Examples of anticoagulants used in the present invention include EDTA or heparin.
- The term “buffy coat” in this invention, is to be understood as the fraction of non-coagulated blood, preferably obtained by means of a density gradient centrifugation, whereby the fraction is enriched with white blood cells and platelets.
FIG. 3 shows a schematic representation of a 3-phase distribution of a blood sample obtained by means of centrifugation. The buffy coat is the middle phase B, located between the plasma-phase A and the erythrocyte-phase C. - In particular, the buffy coat will be isolated from the other fractions and diluted by means of a suitable physiological buffer, such as for example, a phosphate, bicarbonate, or Tris buffer, preferably with a minimum ratio of 1:2. This dilution factor is important, as lower dilution factors may lead to problems when loading the sample from step c on the density gradient, mainly due to a too heavy buffy coat fraction.
- Preferably, the density gradient in step c and d of the present method is obtained by means of Percoll®. More in particular, the Percoll® will comprise a density between the de 1.08 g/ml and 1.077 g/ml.
- The term blood-inter-phase is to be understood as that fraction of the blood, preferably obtained by means of a density gradient, located between the bottom fraction, mainly consisting of erythrocytes and polymorph nuclear cells, and the upper fraction, mainly consisting of plasma polymorph nuclear cells. The blood-interphase is the source of blood mononuclear cells (BMCs) comprising monocytes, lymphocytes, and mesenchymal stem cells.
- By preference, the lymphocytes are washed away at 37° C., while the monocytes die within 2 weeks in the absence of cytokines necessary to keep them alive. In this way, the MSCs are purified. The isolation of the mesenchymal stem cells from the blood-inter-phase is preferably done by means of centrifugation of the blood-inter-phase (after isolation of the inter-phase), after which the cell pellet is washed at least once with a suitable buffer, such as a phosphate buffer.
- In particular, the mesenchymal cells are kept at least 2 weeks in growth medium. Surprisingly, the dexamethasone in the growth medium will cause the stem cells to retain their specific characteristics and keep/prevent them from differentiating. Preferably, 1% dexamethasone is used.
- Following a minimum period of 2 weeks (14 days), preferably 3 weeks (21 days) mesenchymal stem cell colonies will become visible in the culture bottles.
- In a subsequent step g) at least 6×103 stem cells/cm2 are transferred to an expansion medium containing low glucose, serum and antibiotics for the purpose of expanding the mesenchymal stem cells.
- In particular, this medium will include a maximum of 20% serum (such as FBS or FCS). Too high serum concentrations can lead to a kind of “habituation phase” of the mesenchymal stem cells to the growth factors present in the serum, which can lead to a suboptimal division of the cells in the absence of serum. This can adversely affect the cells when they are used for regenerative purposes. Preferably, the expansion of the mesenchymal stem cells will occur in minimal five cell passages. In this way sufficient cells can be obtained. Preferably, the cells are split at 70 to 80% confluency. The mesenchymal stem cells can be maintained up to 50 passages in culture. After this the risk of loss in vitality, senescence or mutation formation occurs.
- The cell population obtained by the method preferably consists of 90% mesenchymal stem cells. More preferably, it will consist of at least 95% mesenchymal stem cells, more preferably of at least 99%, most preferably 100%.
- The nature of the cells obtained through this method can be ascertained by means of markers, specific for mesenchymal stem cells. Preferably, markers are selected from the group consisting of vimentin, fibronectin, Ki67, or any combination thereof. As such the purity of the obtained cell populations can be analyzed, and the percentage of mesenchymal stem cells determined.
- Preferably, the stem cells used in the present invention are isolated from the blood of mammals, more preferably, from peripheral blood. By preference the used blood will originate from human, cat, dog or horse, most preferably equine derived.
- In a possible embodiment, blood from a donor was used who was later also recipient of his isolated mesenchymal stem cells. In another embodiment, blood is used from donors in which the donor is preferably of the same family, gender or race as the recipient of the mesenchymal stem cells isolated from the blood of donors.
- In particular, these donors will be tested on common current transmittable diseases or pathologies, in order to avoid the risk of horizontal transmission of these pathologies or diseases through the stem cells. Preferably, the donor animals are kept in quarantine. When using donor horses they can be, for example tested for the following pathologies: equine infectious anemia (EIA), equine rhinopneumonia (EHV-1, EHV-4), equine viral arteritis (EVA), West Nile virus (WNV), African Horse Sickness (AHS), Dourine (Trypanosoma), piroplasmosis, glanders (malleus, glanders), equine influenza A, Borreliosis (Borrelia burgdorferi, Lyme disease).
- In a final aspect, the current invention also relates to a composition comprising MSCs induced towards tenocytes or chondrocytes; tenocytes or chondrocytes, obtained from a method as described above. Said composition preferably comprises between 1 and 10×106 cells/ml, preferably between 2 and 5×106 cells/ml. Said cells are by preference suspended in a suitable cell medium, such as for instance DMEM. In order to ensure the quality of the cells during cryopreservation, a suitable amount of cryoprotectant is added. Such cryoprotectant may for instance be DMSO. In a preferred embodiment, said DMSO is added in a volume of 10%. Cells are preferably kept at −80° C. prior to use.
- Cells for freezing are obtained after an induction time of typically between 1 to 36 hours. Cultured cells are washed with a saline buffer such as PBS and treated with a solution comprising trypsin and/or EDTA for detaching the cells, preferably at a temperature of 37° C. After the cells have detached, trypsin action is inactivated by adding warm (37° C.) medium to the cells. The cell solution is subsequently centrifuged to obtain a cell pellet. Solution is preferably centrifuged at 300 G for a period between 5 and 10 minutes, more preferably 8 minutes, at room temperature. Supernatants is subsequently removed and cells are re-suspended towards the required cell concentration.
- In particular, the composition is formulated for intravenous, intra-articular, intramuscular, intra-lesional administration to mammals. These modes of administration will depend heavily on the desired application of stem cells and/or their differentiated form.
- In one embodiment, especially when said composition is used for joint or tendon pathologies, can be used with components selected from the group consisting of platelet-rich plasma (PRP), hyaluronic acid, compositions based on hyaluronic acid, glycosaminoglycans, or compositions based on glycosaminoglycans. Mixing of the composition with such carrier substances may in some cases be desirable to increase the effectiveness of the composition or create a synergistic effect. PRP, for example, a substance rich in growth factors, stimulate the stem cells after implantation. Preferably, both the stem cells and PRP are harvested from the same donors are for compatibility reasons. Carrier substances can also be used to counteract gravity: stem cells follow the law of gravity and therefore have difficulties reaching higher lesions without a carrier in which they can migrate. In addition, the carrier substances themselves also have beneficial effects on the pathological environment in which they contribute to the tissue repair itself and also provide a good stem cell niche to help differentiation of the cells in this area. Examples of hyaluronic acid, glycosaminoglycans or compositions on this basis include OSTENIL®, OSTENIL® +, Adant® and Adequan®.
- The composition according to the present invention has very broad applicability. In particular, the composition is suitable for the following purposes:
-
- treatment of trauma selected from the group comprising trauma of cartilage, tendon traumas, traumas of the ligaments, traumas of the bones, traumas of the mucus membranes, cysts or fractures
- treatment of neurological and neurodegenerative diseases selected from the group of Cushing's syndrome, respiratory paralysis or paresis of the extremities, and/or
- treatment of acute or chronic inflammatory disease states selected from the group of laminitis, periostitis, gastritis, osteoarthritis, inflammation—treatment of hypersensitivity reactions such as insect hypersensitivity (summer eczema for example), drug hypersensitivity, hypersensitivity to dust and other types of hypersensitivity.
- In particular, comprises the current invention each application whereby a subject benefits from administering the composition to said subject. The subject may include a horse, cat, dog or human. More particularly, a method for administering a composition according to the present invention to a subject, may include the following steps:
-
- a) thawing a sample bottle comprising the composition, frozen at at least −80° C., whereby thawing is carried out at a temperature between 20° C. and 37° C., preferably between 25° C. and 37° C., and in a time span of maximal 20 minutes, more preferably maximal 5 minutes;
- b) aspirating the sample from the sample vial by means of a needle with an inner diameter of at least 0.3 mm, preferably at least 0.35 mm;
- c) optional mixing of the composition with components selected from the group of platelet-rich plasma (PRP), hyaluronic acid or glycosaminoglycans;
- d) administrating the composition or mixture thereof to a subject by intravenous, intra-articular, intramuscular, intra-lesional injection.
- The cell diameter of the injection needle is crucial in this respect, in order to avoid damage to the cells. Defrosting the composition can be accomplished by thawing in a hot water bath or in the palm of one's hand or by any other method within the temperature limits.
- Preferably, the composition is administered within 2 minutes after thawing, in order to safeguard the vitality of the composition.
- In what follows, the invention is described on the basis of non-limiting examples which illustrate the invention, and are not intended to limit the scope of the invention.
- The following are examples of possible medium according to the current invention, useful for either tenogenesis or chondrogenesis. It is to be understood that the growth factors as defined in the tables below can be replaced by other growth factors of the same superfamily, or that the final concentration of a growth factor can be interchanged by a combination of growth factors of the same superfamily, whereby the sum of the concentrations of the combined growth factors equals the final concentration of the similar growth factor alone.
-
TABLE 1 Chondrogenic medium Medium A Medium B Medium C Medium D Medium E FGF-2 3 ng/ ml 4 ng/ ml 5 ng/ml TGF- β3 4 ng/ ml 3 ng/ml 7 ng/ ml 5 ng/ml IGF-I 120 ng/ml 210 ng/ml 80 ng/ml -
TABLE 2 Tenogenic medium Medium A Medium B Medium C Medium D Medium E FGF-2 5 ng/ml 7 ng/ ml 4 ng/ ml 10 ng/ ml 3 ng/ml TGF- β3 1 ng/ ml 3 ng/ml IGF-I 10 ng/ml - Cells were seeded at a concentration of 6 to 14×103 MSCs/cm2 in cell inducing medium. The following media were used:
-
- Tenogenic medium: DMEM Low Glucose+20% FCS+1% P/S+5 ng/ml FGF-2
- Chondrogenic medium: DMEM Low Glucose+20% FCS+1% P/S+4 ng/ml TGF-B3+120 ng/ml IGF-I
- In the chondrogenic induced cells, cartilage gene expression (Aggrecan (ACAN), Cartilage Oligomeric Matrix Protein (COMP) and
Collagen 2A (COLL 2A)) were found to be increased after 1 day induction (seeFIG. 1A ) (RT-PCR results). In tenogenic induced cells, tendon gene increase (Collagen I and III) and cartilage gene decrease (Collagen II) was noticed within a time span of 1-7 days (depending on the experiment) (seeFIG. 1B ). - The results clearly demonstrate the variability in stem cell properties and pureness between the different sources.
- The inventors furthermore checked the difference in tenogenic “inducive” potential between MSCs derived from human adipose tissue (AT), umbilical cord blood (UC) or bone-marrow derived MSCs (BM). Cells were isolated according to known protocols. It was found that BM MSCs gave slightly better results than AT MSCs. The overall collagen ratio in AT-MSCs derived cells prior to induction is very high, which seems to have an impact on the induction and differentiation (resulting in a steep decrease in collagen type I and III) (
FIG. 2A ). The BM MSCs on the other hand, show a limited increase in collagen type I, yet a decrease in collagen type III, which is a good thing on the long run. However, an overall increase of both collagen types, preferably with a steeper collagen type I increase is to be pursued (to avoid a too long remodeling phase in vivo). The results of the UC MSCs embody this exactly (FIG. 2C ): an increase in collagen type I and III, yet a higher level of collagen type I and a low amount of the cartilage collagen type II (as in the other groups). - In conservative tendon healing, the acute phase consists of an increase in collagen type III, which will be replaced by the more elastic collagen type I. With the tenogenic induced UC MSCs in humans or blood-derived MSCs, it is possible to mimic this increase in a faster rate, while avoiding a too long remodeling phase, because of the higher amount of collagen type I.
- a. Isolation and Tenogenic Induction of Mesenchymal Stem Cells (MSCs)
- In total 50 ml of blood was collected in sterile EDTA tubes from the vena jugularis of the 6-years-old donor gelding for mesenchymal stem cell (MSC) isolation. At the same time, serum was collected and sent to Bose laboratory (Harsum, Germany) for testing on the following transmittable diseases: Equine infectious anemia (EIA), Equine rhinopneumonia (EHV-1, EHV-4), Equine Viral Arteritis (EVA), West-Nile Virus (WNV), Afrikan Horse Sickness (AHS), Dourine (Trypanosoma), Piroplasmosis, Malleus, Glanders, Equine Influenza A (equi I and II, American and European type) and Borreliosis (Borrelia Burgdorferi, the Lyme disease). Three weeks later, a second blood sample was sent to Bose again in order to confirm if antibody production was due to vaccination. After arriving in the lab, the 50 ml of blood was centrifuged at 1000 G for 20 minutes and the buffy coat was collected and diluted 1:2 with phosphate-buffered saline (PBS). Afterwards, this suspension was gently layered on an equal amount of percoll (GE Healthcare). The further isolation was performed as described above. Then, 20 million peripheral blood mononuclear cells (PBMCs) were seeded per T75 flask in 3 flasks and cultured in culture medium. The medium was refreshed twice a week and the cells were maintained at 37° C. and 5% CO2. At 60% confluency the cells were trypsinized with 0.25% trypsin-EDTA and subcultured in tenogenic inducing medium (DMEM LG+20% FCS+1% P/S+FGF(−2) (5 ng/ml).) for 3 days. At the next confluency, the cells were trypsinized and resuspended in 1 ml of DMEM low glucose with 10% of dimethyl sulfoxide (DMSO, Sigma). At this point the cells were frozen overnight in isopropanol at −80° C. The samples were then stored in −80° C. and shipped on dry-ice before clinical application.
- b. Preparation of Platelet-Rich Plasma (PRP)
- In total 300 ml of peripheral blood was taken in a citrate phosphate dextrose adenine-1 (CPDA-1) single blood bag (Terumo®) for platelet-rich plasma (PRP) preparation. From this
donor horse 25 samples of 1 ml PRP were prepared as previously described [Araki et al., 2012]. Each sample contained approximately 200×106 platelets and was frozen and stored at −80° C. before clinical application. - c. Immunohistochemistry
- Immunohistochemistry (IHC) was performed to evaluate the expression of markers present on tenogenic induced MSCs. Cells were fixed for 10 minutes with 4% PF and permeabilized for 2 minutes with 0.1% Triton X at room temperature. Subsequently, cells were incubated with hydrogen peroxide (0.03%) for 5 minutes at room temperature and after washing with PBS, incubated for 2 hours at room temperature with the primary mouse IgG2a monoclonal anti-human smooth muscle actin (SMA) antibody (Dako, 1:200) and the rabbit IgG polyclonal anti-human collagen type IA2 (Col IA2) antibody (Abcam, 1:100). After washing with PBS, secondary ready to use goat anti-mouse and anti-rabbit peroxidase (PO)-linked antibodies (Dako) were added and incubated for 30 minutes at room temperature. Finally, 3,3′-diaminobenzidine (DAB) was added for 2-10 minutes and a counter staining with hematoxylin was performed to visualize the surrounding cells. As controls, identical stainings were performed on undifferentiated MSCs and background staining was assessed by using the proper isotype-specific IgG's. All isotypes were matched to the immunoglobulin subtype and used at the same protein concentration as the corresponding antibodies.
- Injecting Mesenchymal Stem Cells (MSCs) and Scoring System
- After thawing, the tenocytes (1 ml) and PRP (1 ml) were aspirated in the same syringe and intralesionally administered by means of ultrasound guidance. Twenty five acceptor horses were selected based on their injuries: a clear lesion had to be visible on the ultrasound at the lateral edge of the superficial digital flexor tendon (SDFT, n=10) or at the lateral branch of the suspensory ligament (SL, n=15). Clinical lameness was also noticeable in most of the cases. Afterwards, the horses were closely monitored for 1 week by means of a daily examination of their tendons and by observing possible adverse effects or hypersensitivity reactions (wheal formation, sweating, strong respirations or even fever). Subsequently, the tendons were evaluated at approximately 6 weeks post injection through ultrasound imaging and by lameness evaluation. Four veterinary practitioners were asked to give a score between 0 and 5 for their ultrasound images at approximately 6 weeks after the treatment. A score of 0 corresponded with 0% improvement or no ultrasonic improvement; 1=20% improvement or little ultrasonic improvement, but less than after conservative treatment; 2=40% improvement or greater ultrasonic improvement, as is usually seen after a successful conservative treatment; 3=60% improvement or better ultrasonic improvement than after successful conservative therapy; 4=80% improvement or very good ultrasonic improvement, much better than after successful conservative therapy, but not yet fully recovered; 5=100% improvement or no ultrasonic abnormalities, the tendon has the same consistency and fiber orientation as the contralateral tendon.
- d. Isolation and Tenogenic Induction of Mesenchymal Stem Cells (MSCs)
- After 17 days the first spindle shaped cells were noticed in the culture flasks and at 21 days after isolation the cells were trypsinized at approximately 60% confluency. Light microscopic images (LM) of the isolated cells as well as after tenogenic induction are depicted in
FIG. 3 . Undifferentiated MSCs had a stellate/spindle-shaped morphology and grew in colonies. After tenogenic induction, the cells showed a stretched morphology and fiber orientation could be noticed after 3 days of culturing in the tenogenic inducing medium. - e. Immunohistochemistry
- After 3 days of tenogenic induction, the cells were all positive for smooth muscle actin (SMA) which strongly indicates that they gained in elasticity (
FIG. 4 ). Moreover, some of the cells started to produce collagen type I, which is the functional tendon collagen (FIG. 5 ). These results implicate that tenogenic induction was successful, but that the cells were not terminally differentiated towards tenocytes, because the extracellular matrix production remained limited. This was in fact one of our objectives, since we were aiming to induce the MSCs towards tenocytes without producing all the extracellular matrix components in vitro before their in vivo application. - f. Scoring of the Ultrasound Images
- It has been reported that frozen equine PB-derived MSCs do not lose their stem cell characteristics [Martinello et al., 2010]. In this regard, the use of frozen tenogenic induced samples was defensible. After the treatment with allogenic tenogenic induced MSCs, the horses were closely monitored and no adverse effects could be noticed by the attending veterinarian nor by the owners. After approximately 6 weeks, in all 10 horses with a lesion in the lateral edge of the superficial digital flexor tendon (SDFT) a
score 3 or more was given (60% improvement or better ultrasonic improvement than after successful conservative therapy) (FIG. 6 ). Indeed, the ultrasound images ofFIG. 7 show that there is asubstantial improvement 39 days after the treatment on the longitudinal (left images) as well as the transversal ultrasound images (right images). In addition, it should be mentioned that 4 out of the 10 horses (40%) even had a score 5 (100% improvement or no ultrasonic abnormalities, the tendon has the same consistency and fiber orientation as the contralateral tendon) at 6 weeks after the treatment (FIG. 6 ). After approximately 6 weeks, in 14 out of 15 horses with a lesion in the lateral branch of the suspensory ligament (SL) ascore 3 or more was given as well (FIG. 6 ). Moreover, as for the SDFT lesions, 40% of the horses with a SL lesion (6 out of 15) received a score 5 (FIG. 6 ). Also here, ultrasound images revealed promising results as shown inFIG. 8 . In addition, it should be noticed that even a calcification (black arrow) did not hinder the tenogenic induced MSCs to fill up the defect without further calcifying the tendon, which was the goal of the present study. - MSCs and PRP were prepared as described in Example 4.
- a. Case Selection and History
- Eight adult Warmblood show jumping horses were included in this study. The horses showed the following clinical signs: acute lameness in one of the front limbs (one of the horses was lame after a jumping exercise), swelling, warmth and sensitivity in the area of the accessory ligament of the deep digital flexor tendon (ALDDFT). Moreover, all lesions of the ALDDFT had to be clearly detectable on ultrasound examination, and none of the horses could have received any treatment before inspection by the non-blinded attending veterinarians. In addition, horses with lesions in other structures besides the ALDDFT were excluded from the study.
- b. Treatment Protocol
- When desmitis of the ALDDFT was diagnosed, the horses were initially treated conservatively for 5 days with non-steroidal anti-inflammatory drugs (NSAIDs), resting, cooling and a compressive bandage in order to reduce the swelling of the region and obtain optimal conditions for the intralesional injection. After conservative treatment, an intralesional injection of PRP or a tenocyte induced cell composition according to the current invention was randomly assigned to each horse and performed using ultrasound guidance. All 8 horses were immobilized (box rest) for 3 weeks, followed by daily walking exercises for 5 to 10 minutes for another 3 weeks. The first follow-up was planned 6 weeks after the injection. A second clinical and ultrasonographic examination was performed at 4 months after treatment.
- c. Evaluation Protocol
- The horses were re-evaluated clinically and ultrasonographically 6 weeks and 4 months after the injection with PRP or the cell composition. The clinical examination consisted of a visual inspection, palpation for the presence of swelling and/or heat, general inspection of the patient and a concise lameness evaluation. A thorough ultrasound examination was performed at the lesion site. There were several reasons for performing ultrasonographic diagnoses. The ease, safety and non-invasiveness of this method permitted not only a morphologic in vivo evaluation of the lesions, but, more importantly an observation over time. Thanks to the technological advances and decreasing equipment cost, this imaging modality is very useful and readily available in practice. Two veterinary practitioners were asked to give a score between 0 and 5 for the ultrasound images of all the patients. The scoring system was adapted from a previous study about superficial digital flexor tendinitis and desmitis of the suspensory ligament by Broeckx et al, 2012. The threshold for improvement after successful conservative therapy was set at maximal 40% at 6 weeks and 60% at 4 months after conservative treatment. A score of 0 corresponded with 0% improvement or no ultrasonographic improvement; 1=20% improvement or little ultrasonographic improvement; 2=40% improvement or the same ultrasonographic improvement as expected after 6 weeks of conservative treatment; 3=60% improvement or better ultrasonographic improvement as expected after 6 weeks of conservative treatment or the same ultrasonographic improvement as expected after 4 months of conservative treatment; 4=80% improvement or very good ultrasonographic improvement, much better than seen after 4 months of conservative treatment, but not yet fully recovered; 5=90-100% improvement or (nearly) no ultrasonographic abnormalities, the ligament has (almost) no hypo-echoic foci and (nearly) the same fiber orientation as the contralateral ligament.
- c. Isolation and Tenogenic Induction of Mesenchymal Stem Cells (MSCs)
- Blood was sampled according to an ethically approved methodology. After 17 days the first spindle shaped cells were noticed in the culture flasks and at 21 days after isolation the cells were trypsinized at approximately 60% confluency. The isolated cells had a stellate/spindle shaped morphology (
FIG. 9 ) and fulfilled all the requirements to be typed as mesenchymal stem cells (MSCs). After 3 days of tenogenic induction, the cells showed a stretched morphology and fiber orientation in vitro (FIG. 9 ). The samples were stored in a −80° C. ultralow temperature freezer (Haier, Elscolab) and shipped on dry-ice before clinical application. After thawing, an average cell viability of 85% was noticed in all the samples. - d. Preparation of Platelet-Rich Plasma (PRP)
- Concerning the platelet-rich plasma (PRP) preparation, each sample contained approximately 200×106 platelets per ml and was frozen and stored at 1 ml per sample in a −80° C. ultralow temperature freezer (Haier, Elscolab) before clinical application. In addition, it has to be mentioned that for all the tenocyte induced compositions and PRP samples bacteriological, fungal and yeast examinations were performed. Obviously, only the samples that were negative for the microbiological examinations were released for clinical use. To ensure conformity in the study, a liquid form of PRP was used. In this regard, we were able to compare the tenocyte induced composition with PRP using the same treatment protocol and similar carrier fluids.
- e. Patient Follow-Up
- In the days following the intralesional injection, particular attention was paid to observing any possible adverse effect or hypersensitivity reaction, which would be noticeable in the form of wheal formation (physical reaction), local warmth, sweating, heavy breathing or fever. In all 8 horses there were no signs of any of the general adverse effects, which could have been expected, since the horses were injected locally. In contrast with the tenocyte induced composition treated patients, the 4 horses treated with PRP showed a more pronounced swelling during 5 days after injection, which disappeared without medical treatment (
FIG. 10 ). At the re-evaluations at 6 weeks and 4 months post injection (FIG. 10 ), none of the horses presented local adverse effects after treatment with PRP or the tenocyte induced composition in the accessory ligament of the deep digital flexor tendon (ALDDFT). - All the horses treated with PRP were still lame at approximately 6 weeks post injection, the ALDDFT region was faintly swollen and ultrasound images were only slightly improved. Therefore, a
score 2/5 was given by 2 independent veterinarians to all 4 patients (FIG. 11 ). In the tenocyte induced treated group, on the other hand, all 4 horses were clinically sound, the swelling disappeared and the same 2 independent veterinarians gave ascore 4/5 for the ultrasound images at 6 weeks after intralesional injection (FIG. 11 ). This implicates that the lesions improved about 80% on the ultrasound images, which was much better than the 40% improvement in the PRP treated group.FIG. 12 represents the ultrasound images of 3 patients before and 6 weeks after treatment with tenocyte induced cell composition. A considerable filling of the lesions could be noticed in all cases. Still, the lesions were not completely filled, and therefore, the patients were advised to continue and increase the walking exercise for 3 more weeks, followed by trotting exercise until 4 months after the treatment. - Four months after the intralesional PRP injections, the horses were faintly lame (only visible under certain circumstances) and the attending veterinarians assigned a
score 3/5 (FIG. 11 ), which was still not comparable with 6 weeks after tenocyte treatment. At 4 months after tenocyte treatment, 3 of the 4 horses received ascore 5/5 and went back to full training. However, 1 of the 4 horses slightly relapsed (non-pronounced lameness) and received ascore 3/5, as in the PRP group (Table 4,FIG. 11 ). In conclusion, this study reports a positive clinical and ultrasonographical outcome after tenogenic induced MSC treatment of desmitis of the equine ALDDFT, whereas no considerable improvements could be noticed after treatment with allogenic PRP. - MSCs and PRP were prepared as described in Example 4.
- a. Chondrogenic Induction of Mesenchymal Stem Cells (MSCs)
- After MSC isolation, cells were seeded at 6.7×103 MSCs/cm2 in T75 flasks for chondrogenic induction. Chondrogenic induction medium comprised of DMEM Low Glucose, 20% FCS, 1% AB/AM and 4 ng/ml TGF-β3+120 ng/ml IGF-I. At 60% confluency, chondrogenic induced cells were trypsinized, resuspended in 1 ml of DMEM low glucose with 10% of dimethyl sulfoxide (DMSO, Sigma) and frozen before being shipped on dry-ice for clinical application.
- b. Preparation of Platelet-Rich Plasma (PRP)
- In total, 300 ml of peripheral blood was taken in a citrate phosphate dextrose adenine-1 (CPDA-1) single blood bag (Terumo®) for platelet-rich plasma (PRP) preparation. From this donor horse, 30 samples of 1 ml PRP were prepared. Each sample contained approximately 200×106 platelets and was frozen and stored at −80° C. before clinical application.
- c. Cytological Staining
- Hematoxylin (HE), Crystal Violet (CV), Alcian Blue (AB) and Safranin O (SO) staining (all from Sigma) were performed on MSCs and chondrogenic-induced MSCs, as indicated by the manufacturer. Both HE and CV staining were carried out in order to visualize the cell morphology and cellular organization. Furthermore, AB and SO staining were performed to give an indication of the presence of acid polysaccharides, such as glycosaminoglycans in cartilage-like structures.
- d. Immunocytochemistry
- Immunocytochemistry was performed to evaluate the expression of collagen type II (Col II), Ki67 (proliferation marker), p63 (tumor suppression gene) and vimentin (mesenchymal cell marker) on native MSCs and chondrogenic-induced MSCs after trypsinization and cytospin preparation at 700 rpm for 4 minutes. Cells were fixed for 10 minutes with 4% PF and permeabilized for 2 minutes with 0.1% Triton X at room temperature. Subsequently, cells were incubated with hydrogen peroxide (0.03%) for 5 minutes at room temperature and after washing with PBS, incubated for 30 minutes at room temperature with the primary rabbit IgG polyclonal antibodies recognizing: Col IIA1 (1:50), Ki67 (1:200) and p63 (1:100) and mouse IgG1 monoclonal anti-vimentin (1:100) (all from Abcam). After washing with PBS, secondary ready-to-use goat anti-mouse and anti-rabbit peroxidase (PO)-linked antibodies (Dako) were added and incubated for 30 minutes at room temperature. Finally, 3,3′-diaminobenzidine (DAB) was added for 5 minutes and a counter staining with hematoxylin was performed to visualize the surrounding cells. As controls, identical staining was performed on undifferentiated MSCs and background staining was assessed by using the proper isotype-specific mouse monoclonal or rabbit polyclonal antibody. All isotypes were matched to the immunoglobulin subtype and used at the same protein concentration as the corresponding antibodies. Wherever appropriate, equine tendon or skin tissue sections were used as negative controls.
- e. Flow Cytometry
- To characterize the MSCs immunophenotypically, the expression of several stem cell markers was evaluated by flow cytometry. The expression of the typical rejection proteins, major histocompatibility complex (MHC) class I and II was evaluated on native and chondrogenic induced MSCs. Per series, 400,000 cells were used and labeled with the following primary antibodies: mouse anti-horse MHC class I IgG2a (Washington State University, 1:50) and mouse anti-horse MHC class II IgG1 (Abd Serotec, 1:50). Cells were incubated with the primary antibodies for 15 minutes on ice in the dark and washed twice in washing buffer, consisting of DMEM with 1% bovine serum albumin (BSA). A secondary rabbit anti-mouse-FITC (Abcam, 1:100) antibody was used to identify positive cells after 15 minutes of incubation on ice in the dark. Finally, all cells were washed three times in washing buffer and at least 10,000 cells were evaluated using a fluorescence activated cell sorter (FACS) Canto flow cytometer (Becton Dickinson Immunocytometry systems) equipped with a 488 nm solid state and a 633 nm HeNe laser, and these data were subsequently analysed with the FACS Diva software. All analyses were based on (i) autofluorescence and (ii) control cells incubated with isotype-specific IgG's, in order to establish the background signal. All isotypes were matched to the immunoglobulin subtype and used at the same protein concentration as the corresponding antibodies.
- f. Gene Expression Analysis by Real-Time RT-PCR
- Equine MSCs in
passage 3 were seeded in T25 flasks at a density of 8,000 MSCs/cm2 with either expansion medium (minus the chondrogenic inducing factors) or chondrogenic induction medium for 30 hours. After treatment, cells were lysed in 2 ml of Trizol (Invitrogen) and the lysate was separated into aqueous and organic phases by chloroform separation (300 μl, Sigma-Aldrich). The aqueous phase was recovered after centrifugation and total RNA was precipitated by using equal volumes of isopropanol. The precipitate was washed with 75% EtOH once and then solubilized with 25 μl of RNAse free water and quantified on the Nanodrop Lite (Fisher Scientific) before reverse transcribing 1 μg of RNA, using the TaqMan Reverse Transcription Reagents Kit (Life Technologies). Gene expression analysis was performed in triplicate (30 ng of cDNA in each reaction) with TaqMan Gene Expression Assays (Life Technologies) (Table 3) on the CFX96 Real-Time PCR System (Biorad). Values were normalized to GAPDH mRNA as internal control and presented as fold change, compared to native MSCs (i.e. in expansion medium), using the comparative CT method (=2-ΔΔCT method). -
TABLE 3 TaqMan gene expression assays used for real-time RT-PCR Target gene Assay ID Aggrecan Ec03469667_m1 Collagen II Ec03467386_g1 COMP Ec03468079_g1 GAPDH Ec03210916_gH - g. Patient Inclusion Criteria
- For a first study, 20 acceptor horses were selected based on their injuries. Clinical lameness had to be present in a mild to moderate form for at least 3 months and had to be attributable to fetlock joint osteoarthritis. In this regard, the location of the lameness had to be confirmed by a positive intra-articular anesthesia of the fetlock joint, a mild to moderate positive flexion test and a certain degree of joint effusion. Furthermore, signs of osteoarthritis such as osteophytes and/or cartilage defects had to be noticeable on CT and/or radiography. For a second study (comparing 2 combination treatments), 30 horses were selected using the same inclusion criteria. Untreated or placebo animals could not be included in the present study, since only owner horses with naturally occurring DJD were used.
- Injecting mesenchymal stem cells (MSCs) and monitoring of adverse reactions In the first study, horses were randomly assigned to PRP, native MSCs, native MSCs plus PRP (Combination 1), or chondrogenic-induced MSCs plus PRP (Combination 2) treatment. In the second study, horses were randomly assigned to one of the two combination therapies. After thawing, both MSCs and PRP were aspirated in the same syringe (for combination groups) and administered intra-articulary. After the treatment, the horses were closely monitored for 1 week by means of a daily examination of the injected joint and by observing the occurrence of possible adverse effects or hypersensitivity reactions (wheal formation, sweating, strong respirations or even fever). Subsequently, the joints were evaluated at approximately 6 weeks (T1), 12 weeks (T2), 6 months (T3) and 12 months (T4) post injection through clinical evaluation by 2 independent veterinarians for all horses. In the second study, horses were randomly assigned to one of the two combination therapies and evaluated at T1. The experimental design was approved by an ethical committee.
- h. Clinical Scoring System
- In order to evaluate the severity of the clinical condition, the following parameters were graded by the same veterinarians at the aforementioned time points (T0-4): clinical lameness from 0 to 5 (0=no lameness and 5=minimal weight bearing lameness) according to the American Association of Equine Practitioners (AAEP), response to flexion test from 0 to 3 (0=no flexion response and 3=severe flexion response) and fetlock joint effusion from 0 to 2 (0=no swelling and 2=severe swelling). All the horses in this study showed initially a mild to moderate lameness (1-2 out of 5), mild to moderate response to flexion test (1-2 out of 3) and moderate to severe joint effusion (1-2 out of 2). As a result, all horses had a very similar initial clinical score of 4-5 out of 10. Because the importance of each parameter was correlated with its impact, the sum of these 3 parameters was reckoned as the overall clinical severity score (0 to 10), with 0 corresponding to clinical soundness. The progress of the overall scores (compared to before the treatment) was translated in a positive evolution score ranging from 0 to 5: 0=severity score of 5 out of 10; 1=severity score of 4 out of 10; 2=severity score of 3 out of 10; 3=severity score of 2 out of 10; 4=severity score of 1 out of 10; and 5=return to clinical soundness or severity score of 0 out of 10. Severity scores were translated to evolution scores for easier interpretation of the data and a positive trend would therefore indicate a clinical improvement. Statistical analysis was performed based upon the clinical evolution scores.
- i. Statistical Analysis
- For data analysis in
study 1, the average of the evolution scores at 6 and 12 weeks represented the early evolution score, and the average of the evolution scores at 6 and 12 months represented the late evolution score. The early and late evolution scores are compared between the group receiving both MSCs (either native or induced) and PRP and the group receiving only MSCs on the one hand or receiving only PRP on the other hand, using the Wilcoxon signed rank sum test at the 5% significance level. Furthermore, within the combined treatment (study 2), the chondrogenic-induced MSCs are compared with native MSCs only for the earliest evolution score (i.e. at 6 weeks) equally using the Wilcoxon signed rank sum test at the 5% significance level. - j. Isolation of Mesenchymal Stem Cells (MSCs)
- The first spindle shaped cells were noticed after 17 days in culture and were isolated at 21 days at approximately 60% confluency.
- k. Characterization and Chondrogenic Induction of MSCs
- To initially characterize MSCs and confirm chondrogenic induction, we analyzed cell morphology by light microscopy utilizing HE and Crystal Violet staining. Biochemical induction was analyzed by measuring gene and protein expression of selected cell markers (glycosaminoglycan production, collagen type II (Col II), Ki67 p63, vimentin, major histocompatibility complex, aggrecan, cartilage oligomeric matrix protein) providing insight into the degree of chondrogenic-induction by real-time RT-PCR, Alcian Blue staining, Safranin O staining, immunocytochemistry and flow cytometry.
- Light microscopic analysis in conjunction with HE and Crystal Violet staining showed that native MSCs (
FIG. 13A & C) had a stellate/spindle-shaped morphology and displayed a propensity to grow in colonies, whereas MSCs induced into the chondrogenic lineage (FIG. 13B & D) showed a more rectangular morphology. In addition, a few chondrocyte-like cells in lacune-like structures could be noticed after 3 days of culturing in the chondrogenic-inducing medium (FIG. 13D ). Gene expression analysis confirmed the switch towards a chondrogenic phenotype, exhibiting increases in the levels of Col II, aggrecan (ACAN) and cartilage oligomeric matrix protein (COMP) in induced MSCs, compared to native MSCs (FIG. 14 ). Histological staining of the cells with both Alcian Blue and Safranin O confirmed the production of glycosaminoglycans in the chondrogenic-induced group (FIG. 15B & D), whereas undifferentiated MSCs stained negative (FIG. 15A & C). - Immunocytochemistry on cytospins revealed that most of the nuclei in the native MSC group were positive for the proliferation marker Ki67, whereas noticeably less nuclei stained positively in the chondrogenic-induced group (
FIG. 16A ). Moreover, native MSCs and chondrogenic-induced MSCs were both positive for Col II (FIG. 16B ). Cytospin analysis further indicated that native and chondrogenic-induced MSCs were immunoreactive for vimentin (FIG. 16C ), while p63 (FIG. 16D ), which is a member of the p53 tumor suppressor gene family, was only detectable in chondrogenic-induced MSCs. Isotype (FIG. 16 ) and negative controls (data not shown) stained negative. - In vitro differentiation towards undesired lineages (i.e. myogenic, endothelial, or smooth muscle differentiation) results in an increase of the expression of the major histocompatibility complex (MHC) classes I and II [Huang et al., 2010]. It is thus of relevance that our differentiation protocol showed no increase in these markers. While MHC class II expression was completely absent in both native and chondrogenic-induced MSCs (P=0.4), MHC class I was expressed in both types of MSCs (P=0.1), but at very low levels (
FIG. 17A & B). - 1. Scoring of the Clinical Lameness
-
Study 1 - The clinical evolution score of each patient per treatment group can be found in Table 4. For the first study, an overview of the average evolution scores after each treatment is presented in
FIG. 18A . The results of the different treatments with respect to the early and late evolution scores can be found in Table 5. The combined treatments were significantly better than the PRP treatment alone, both for the early evolution score (P=0.033) and the late evolution score (P=0.012). No significant differences were found between the combined treatment and the MSC treatment alone. The combined use of chondrogenic-induced MSCs and PRP generated the highest evolution scores, although the difference was not significantly higher than the combined use of native MSCs and PRP for either the early (P=0.530) or late evolution score (P=0.207). -
TABLE 4 Clinical evolution scores for the different treatment groups with average and standard deviation (STD) at different time points. 6 weeks 12 weeks 6 months 12 months GROUP 1 Horse 14 2 2 1 Horse 24 5 4 4 Horse 33 3 3 3 Horse 43 2 2 2 Horse 53 3 3 3 Average 3.4 3 2.8 2.6 GROUP 2Horse 63 4 5 5 Horse 7 0 1 2 2 Horse 8 3 4 5 5 Horse 9 4 4 5 4 Horse 105 5 5 5 Average 3 3.6 4.4 4.2 GROUP 3Horse 11 3 4 4 5 Horse 124 5 5 3 Horse 13 4 5 5 4 Horse 14 5 5 5 5 Horse 153 4 4 4 Average 3.8 4.6 4.6 4.2 GROUP 4Horse 16 4 4 5 5 Horse 17 5 5 5 5 Horse 18 4 4 4 4 Horse 19 5 5 5 5 Horse 204 5 5 5 Average 4.4 4.6 4.8 4.8 -
TABLE 5 Median, minimum (min) and maximum (max) of the early and late evolution score are indicated per treatment: platelet-rich plasma (PRP), native mesenchymal stem cells (MSCs), combination (Comb) 1 (native MSCs and PRP) or Comb 2 (chondrogenic induced MSCs) Early score Late score Treatment median (min; max) median (min; max) PRP 3.0 (2.5; 4.5) 3.0 (1.5; 4.0) MSCs 3.5 (0.5, 5.0) 5.0 (2.0; 5.0) Comb 14.5 (3.5; 5.0) 4.5 (4.0; 5.0) Comb 24.5 (4.0; 5.0) 5.0 (4.0; 5.0) -
Study 2 - The second clinical study was performed in which a total of 30 horses were treated with either native MSCs plus PRP (
Combination 1, n=15) or with chondrogenic-induced MSCs plus PRP (Combination 2, n=15). The horses were only evaluated at the first time point (i.e. 6 weeks post injection). Our results show that 53% ( 8/15) of the horses in the first group received anevolution score 4 or more, versus 73% ( 11/15) in the second group. However, in both treatment groups the average evolution score was approximately the same (3.7 vs 3.8) and no statistically significant (P=0.67) difference could be noticed (Table 6,FIG. 18B ). -
TABLE 6 Clinical evolution scores at 6 weeks after treatment of 15 horses with native mesenchymal stem cells (MSCs) and PRP (Combination 1) or chondrogenic induced MSCs and PRP Combination 1 Combination 2Horse 13 3 Horse 25 4 Horse 34 4 Horse 44 4 Horse 53 3 Horse 65 4 Horse 7 5 4 Horse 8 3 5 Horse 9 5 4 Horse 103 5 Horse 11 3 4 Horse 120 2 Horse 13 5 5 Horse 14 5 4 Horse 153 2 Average 3.7 3.8 - The results indicate that chondrogenic induction can be achieved in equine MSCs and that the combined use of PRP and MSCs (chondrogenic induced or not) significantly improved the functionality and sustainability of damaged joints in horses with mild to moderate lameness, due to fetlock joint osteoarthritis, up to 12 months post treatment. The highest clinical scores were noticed upon treatment with the chondrogenic induced MSCs and PRP.
Claims (19)
1. A composition for treating trauma in a subject, comprising:
isolated mesenchymal stem cells (MSCs), wherein the MSCs are tenogenic-induced and/or chondrogenic-induced, and wherein the trauma is selected from tendon traumas, traumas of the ligaments, and trauma of cartilage.
2. The composition according to claim 1 , wherein the MSCs are derived from blood.
3. The composition according to claim 2 , wherein the blood is peripheral blood.
4. The composition according to claim 1 , wherein said MSCs are equine-derived.
5. The composition according to claim 1 , wherein said MSCs are allogenic MSCs.
6. The composition according to claim 1 , wherein the composition comprises between 1 and 10×106 cells/ml.
7. The composition according to claim 1 , further comprising platelet-rich plasma (PRP), hyaluronic acid and/or glycosaminoglycans.
8. The composition according to claim 1 , wherein the MSCs are suspended in a cell medium comprising a cryoprotectant.
9. The composition according to claim 8 , wherein the medium is Dulbecco's Modified Eagle's Medium Low Glucose (DMEM LG)
10. The composition according to claim 8 , wherein the cryoprotectant is dimethyl sulfoxide (DMSO).
11. The composition according to claim 1 , wherein the MSCs are tenogenic-induced and the trauma is tendon traumas and/or traumas of the ligaments.
12. The composition according to claim 11 , wherein said composition is administered to a subject by means of intra-lesional administration.
13. The composition according to claim 12 , wherein the subject is a horse and wherein the trauma is tendon trauma comprising a lesion of a superficial digital flexor tendon (SDFT).
14. The composition according to claim 12 , wherein the subject is a horse and wherein the trauma is ligament trauma comprising a lesion of a suspensory ligament of the horse or a lesion of an accessory ligament of a deep digital flexor tendon (ALDDFT) of the horse.
15. The composition according to claim 1 , wherein the MSCs are chondrogenic-induced and wherein the trauma is cartilage trauma.
16. The composition according to claim 15 , wherein the composition is administered by means of intra-articular administration.
17. The composition according to claim 15 , wherein said subject is a horse and wherein the cartilage trauma comprises lameness due to fetlock joint osteoarthritis.
18. The composition according to claim 11 , wherein said tenogenic-induced MSCs are induced in vitro towards tenogenesis by means of a cell medium comprising 5 ng/ml FGF-2.
19. The composition according to claim 15 , wherein said chondrogenic-induced MSCs are induced in vitro towards chondrogenesis by means of a cell medium comprising 4 ng/ml TGFβ3 and 120 ng/ml IGF-1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/187,554 US20230295572A1 (en) | 2013-12-06 | 2023-03-21 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/075782 WO2015082014A1 (en) | 2013-12-06 | 2013-12-06 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
US201615038172A | 2016-05-20 | 2016-05-20 | |
US16/689,898 US11634689B2 (en) | 2013-12-06 | 2019-11-20 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
US18/187,554 US20230295572A1 (en) | 2013-12-06 | 2023-03-21 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/689,898 Continuation US11634689B2 (en) | 2013-12-06 | 2019-11-20 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230295572A1 true US20230295572A1 (en) | 2023-09-21 |
Family
ID=49713102
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/038,172 Active 2034-09-30 US10801014B2 (en) | 2013-12-06 | 2013-12-06 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
US16/689,898 Active 2034-12-01 US11634689B2 (en) | 2013-12-06 | 2019-11-20 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
US18/187,554 Pending US20230295572A1 (en) | 2013-12-06 | 2023-03-21 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/038,172 Active 2034-09-30 US10801014B2 (en) | 2013-12-06 | 2013-12-06 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
US16/689,898 Active 2034-12-01 US11634689B2 (en) | 2013-12-06 | 2019-11-20 | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells |
Country Status (4)
Country | Link |
---|---|
US (3) | US10801014B2 (en) |
EP (3) | EP4170019A1 (en) |
CA (1) | CA2928122C (en) |
WO (1) | WO2015082014A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106399233A (en) * | 2016-09-30 | 2017-02-15 | 广州赛莱拉干细胞科技股份有限公司 | Osteogenic inducement culture medium and osteogenic differentiation method |
EP3666298A1 (en) | 2018-12-13 | 2020-06-17 | Global Stem Cell Technology | A collagen formulation suitable for injection |
WO2021041858A1 (en) * | 2019-08-29 | 2021-03-04 | Icahn School Of Medicine At Mount Sinai | Differentiated tendon cells derived from pluripotent progenitor cells and methods of use thereof |
WO2024033462A1 (en) * | 2022-08-11 | 2024-02-15 | Boehringer Ingelheim Vetmedica Gmbh | Mesenchymal stem cells for use in the treatment of insect-bite hypersensitivity in equines |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2251746T3 (en) | 1996-12-06 | 2006-05-01 | Osiris Therapeutics, Inc. | IMPROVED CONDROGENIC DIFFERENTIATION OF HUMAN MESENQUIMATOSE PRECURSOR CELLS. |
IT1394262B1 (en) | 2008-07-17 | 2012-06-01 | Università Degli Studi Di Milano | METHOD FOR VITRO PRODUCTION OF TENOCYTES STARTING FROM MESENCHIMAL STEM CELLS, AS WELL AS RESPECTIVE METHODS FOR THE CHARACTERIZATION OF THESE TENOCYTES AND THOSE MESENCHIMAL STEM CELLS |
JP2013536860A (en) * | 2010-08-31 | 2013-09-26 | クック・ジェネラル・バイオテクノロジー・エルエルシー | Systemic, allogeneic stem cell therapy for the treatment of animal diseases |
WO2013165252A1 (en) * | 2012-05-03 | 2013-11-07 | Erasmus University Medical Center Rotterdam | Culturing of mesenchymal stem cells |
BE1020480A5 (en) * | 2012-10-01 | 2013-11-05 | Global Stem Cell Technology | METHOD FOR INSULATION OF MESENCHYMAL STEM CELLS FROM BIRD BLOOD AND USE THEREOF |
-
2013
- 2013-12-06 EP EP22207893.3A patent/EP4170019A1/en active Pending
- 2013-12-06 US US15/038,172 patent/US10801014B2/en active Active
- 2013-12-06 WO PCT/EP2013/075782 patent/WO2015082014A1/en active Application Filing
- 2013-12-06 EP EP13799605.4A patent/EP3077503A1/en active Pending
- 2013-12-06 EP EP17205940.4A patent/EP3412768A1/en active Pending
- 2013-12-06 CA CA2928122A patent/CA2928122C/en active Active
-
2019
- 2019-11-20 US US16/689,898 patent/US11634689B2/en active Active
-
2023
- 2023-03-21 US US18/187,554 patent/US20230295572A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015082014A1 (en) | 2015-06-11 |
EP3077503A1 (en) | 2016-10-12 |
US10801014B2 (en) | 2020-10-13 |
US11634689B2 (en) | 2023-04-25 |
US20160289639A1 (en) | 2016-10-06 |
EP3412768A1 (en) | 2018-12-12 |
CA2928122C (en) | 2023-12-12 |
US20200095552A1 (en) | 2020-03-26 |
CA2928122A1 (en) | 2015-06-11 |
EP4170019A1 (en) | 2023-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11634689B2 (en) | Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells | |
McCarthy et al. | The comparison of equine articular cartilage progenitor cells and bone marrow-derived stromal cells as potential cell sources for cartilage repair in the horse | |
Broeckx et al. | Regenerative therapies for equine degenerative joint disease: a preliminary study | |
Renzi et al. | Autologous bone marrow mesenchymal stromal cells for regeneration of injured equine ligaments and tendons: a clinical report | |
Reich et al. | Isolation, culture and chondrogenic differentiation of canine adipose tissue-and bone marrow-derived mesenchymal stem cells–a comparative study | |
US20230128397A1 (en) | Prevention and treatment of bone and cartilage damage or disease | |
Fu et al. | Comparative study of the biological characteristics of mesenchymal stem cells from bone marrow and peripheral blood of rats | |
KR101697141B1 (en) | Cellular therapeutic agents for cartilage regeneration | |
WO2015004609A2 (en) | Adherent cells from placenta and use thereof in treatment of injured tendons | |
Guercio et al. | Mesenchymal stem cells derived from subcutaneous fat and platelet-rich plasma used in athletic horses with lameness of the superficial digital flexor tendon | |
JP6713412B2 (en) | Stem cells from mammalian muscle | |
Linon et al. | Engraftment of autologous bone marrow cells into the injured cranial cruciate ligament in dogs | |
US20230346842A1 (en) | Methods and Compositions For Reducing Joint Inflammation Using Mesenchymal Stem Cells | |
Korchunjit et al. | Characterization and allogeneic transplantation of equine bone marrow–derived multipotent mesenchymal stromal cells collected from cadavers | |
Peer et al. | Comparative evaluation of fracture healing potential of differentiated and undifferentiated guinea pig and canine bone marrow-derived mesenchymal stem cells in a guinea pig model | |
Ozeki et al. | Autologous Synovial Mesenchymal Stem Cell Transplantation Suppresses Inflammation Caused by Synovial Harvesting and Promotes Healing in a Micro Minipig Repaired Meniscus Model | |
Åkerlund et al. | Prevention and treatment of bone and cartilage damage or disease | |
Hill | Development of a tissue engineering platform using bovine species as a model: placental scaffolds seeded with bovine adipose-derived cells | |
Baracho Trindade Hill | Development of a tissue engineering platform using bovine species as a model: placental scaffolds seeded with bovine adipose-derived cells | |
Leander | A Comparative Analysis of Equine Mesenchymal Stromal Cells and Dermal Fibroblasts | |
Redmond Hubbard | A Comparison of Equine Adipose Tissue, Bone Marrow and Peripheral Blood as Sources of Mesenchymal Stem Cells | |
Babazadeh et al. | Histopathological Evaluation of Adipose-Derived Mesenchymal Stem Cell on Cartilage Defects of Knee in Male Rabbits. | |
Coyle | Isolation, expansion and characterisation of mesenchymal stem cells from osteoarthritic and osteoporotic donors | |
Iwasa et al. | THE EXPRESSION OF TYPE2 COLLAGEN IS REGULATED BY PTEN IN CHONDROCYTES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: BOEHRINGER INGELHEIM VETERINARY MEDICINE BELGIUM, BELGIUM Free format text: CHANGE OF NAME;ASSIGNOR:GLOBAL STEM CELL TECHNOLOGY;REEL/FRAME:065657/0815 Effective date: 20210830 |